U.S. patent application number 15/519478 was filed with the patent office on 2017-08-17 for compositions and methods for treating cns disorders.
This patent application is currently assigned to Sage Therapeutics, Inc.. The applicant listed for this patent is Sage Therapeutics, Inc.. Invention is credited to Boyd L. Harrison, Gabriel Martinez Botella, Albert J. Robichaud, Francesco G. Salituro.
Application Number | 20170233433 15/519478 |
Document ID | / |
Family ID | 55747454 |
Filed Date | 2017-08-17 |
United States Patent
Application |
20170233433 |
Kind Code |
A1 |
Martinez Botella; Gabriel ;
et al. |
August 17, 2017 |
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
Abstract
Described herein are neuroactive steroids of the Formula (I): or
a pharmaceutically acceptable salt thereof; wherein, R.sup.1,
R.sup.2a, R.sup.2b, R.sup.3 and A are as defined herein. Such
compounds are envisioned, in certain embodiments, to behave as GABA
modulators. The present invention also provides pharmaceutical
compositions comprising a compound of the present invention and
methods of use and treatment, e.g., such for inducing sedation
and/or anesthesia. ##STR00001##
Inventors: |
Martinez Botella; Gabriel;
(Wayland, MA) ; Salituro; Francesco G.;
(Marlborough, MA) ; Robichaud; Albert J.;
(Cambridge, MA) ; Harrison; Boyd L.; (Princeton
Junction, NJ) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Sage Therapeutics, Inc. |
Cambridge |
MA |
US |
|
|
Assignee: |
Sage Therapeutics, Inc.
Cambridge
MA
|
Family ID: |
55747454 |
Appl. No.: |
15/519478 |
Filed: |
October 16, 2015 |
PCT Filed: |
October 16, 2015 |
PCT NO: |
PCT/US15/56066 |
371 Date: |
April 14, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62064957 |
Oct 16, 2014 |
|
|
|
Current U.S.
Class: |
514/176 |
Current CPC
Class: |
C07D 295/033 20130101;
A61K 9/0019 20130101; C07D 249/18 20130101; C07J 75/00 20130101;
C07J 43/003 20130101; A61K 9/0053 20130101; C07D 231/14 20130101;
C07J 13/007 20130101; C07D 249/04 20130101; A61K 31/58 20130101;
A61P 25/00 20180101 |
International
Class: |
C07J 43/00 20060101
C07J043/00; A61K 9/00 20060101 A61K009/00; A61K 31/58 20060101
A61K031/58 |
Claims
1. A compound of the Formula (I): ##STR00054## or a
pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring; R.sup.3 is absent or hydrogen; and
represents a single or double bond, wherein when one of is a double
bond, the other is a single bond; and when one of the is a double
bond, R.sup.3 is absent.
2. The compound of claim 1, wherein R.sup.1 is substituted or
unsubstituted C.sub.1-6 alkyl.
3. The compound of claim 1, wherein R.sup.1 is methyl or
CF.sub.3.
4. The compound of claim 1, wherein R.sup.2a is methyl.
5. The compound of claim 1, wherein R.sup.2b is hydrogen.
6. The compound of claim 1, wherein R.sup.2a is methyl and R.sup.2b
is hydrogen.
7. The compound of any one claim 1, wherein represents a single
bond.
8. The compound of claim 1, wherein the compound of Formula (I) is
a compound of Formula (II) or Formula (III): ##STR00055## or a
pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, and R.sup.2b are defined as for Formula (I).
9. The compound of claim 1, wherein the compound of Formula (II) is
a compound of Formula (II-a) or Formula (II-b): ##STR00056## or a
pharmaceutically acceptable salt thereof, wherein A and R.sup.1 are
defined as for Formula (I).
10. The compound of claim 1, wherein the compound of Formula (III)
is a compound of Formula (III-a) or Formula (III-b): ##STR00057##
or a pharmaceutically acceptable salt thereof, wherein A and
R.sup.1 are defined as for Formula (I).
11. The compound of claim 1, wherein A is heterocyclyl or
heteroaryl.
12. The compound of claim 1, wherein A is monocyclic or
bicyclic.
13. The compound of claim 1, wherein A is substituted with at least
one R.sup.A, wherein R.sup.A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-6 carbocylyl, C.sub.1-6 haloalkyl,
halogen, cyano, --OR.sup.A6, --C(.dbd.O)OR.sup.A6, --SR.sup.B6,
--S(.dbd.O)R.sup.B6, or S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6
is hydrogen or C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, or C.sub.1-6 haloalkyl, and R.sup.B6
is C.sub.1-6 alkyl or C.sub.3-6 carbocylyl.
14. The compound of claim 13, wherein R.sup.A is C.sub.1-6 alkyl,
halogen, or cyano.
15. The compound of claim 13, wherein A is substituted with 1-3
instances of R.sup.A.
16. A compound of the Formula (IV): ##STR00058## or a
pharmaceutically acceptable salt thereof wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring; R.sup.3 is absent or hydrogen; R.sup.A is
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
carbocylyl, C.sub.1-6 haloalkyl, halogen, cyano, --OR.sup.A6,
--C(.dbd.O)OR.sup.A6, --SR.sup.B6, --S(.dbd.O)R.sup.B6, or
S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6 is hydrogen or C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 carbocylyl,
or C.sub.1-6 haloalkyl, and R.sup.B6 is C.sub.1-6 alkyl or
C.sub.3-6 carbocylyl; n is 0, 1, 2 or 3; and represents a single or
double bond, wherein when one of is a double bond, the other is a
single bond; and when one of the is a double bond, R.sup.3 is
absent.
17. The compound of claim 16, wherein R.sup.1 is substituted or
unsubstituted C.sub.1-6 alkyl.
18. The compound of claim 16, wherein R.sup.1 is methyl or
CF.sub.3.
19. The compound of claim 16, wherein R.sup.2a is methyl.
20. The compound of claim 16, wherein R.sup.2b is hydrogen.
21. The compound of claim 16, wherein R.sup.2a is methyl and
R.sup.2b is hydrogen.
22. The compound of claim 16, wherein represents a single bond.
23. The compound of claim 16, wherein the compound of Formula (IV)
is a compound of Formula (V) or Formula (VI): ##STR00059## or a
pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for Formula
(IV).
24. The compound of claim 16, wherein the compound of Formula (V)
is a compound of Formula (V-a) or Formula (V-b): ##STR00060## or a
pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for Formula
(IV).
25. The compound of claim 16, wherein the compound of Formula (VI)
is a compound of Formula (VI-a) or Formula (VI-b): ##STR00061## or
a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, are
defined as for Formula (I).
26. The compound of claim 1, wherein A is selected from:
##STR00062##
27. The compound of claim 1, wherein A is selected from:
##STR00063##
28. The compound of claim 1, wherein the compound is selected from:
##STR00064## ##STR00065## ##STR00066## ##STR00067##
29. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable excipient.
30. A method of inducing sedation and/or anesthesia in a subject,
comprising administering to the subject an effective amount of a
compound of the Formula (I): ##STR00068## or a pharmaceutically
acceptable salt thereof, wherein: A is aryl, heterocyclyl or
heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is C.sub.1-6
alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or R.sup.2a and
R.sup.2b are joined to form an oxo (.dbd.O) group; or R.sup.2a and
R.sup.2b together with the carbon atom to which they are attached
form a ring; R.sup.3 is absent or hydrogen; and represents a single
or double bond, wherein when one of is a double bond, the other is
a single bond; and when one of the is a double bond, R.sup.3 is
absent.
31. A method of administering an effective amount of a compound, a
pharmaceutically acceptable salt thereof, or pharmaceutical
composition of claim 1 to a subject in need thereof, wherein the
subject experiences sedation and/or anesthesia within two hours of
administration.
32. The method of claim 31, wherein the subject experiences
sedation and/or anesthesia within one hour of administration.
33. The method of claim 31, wherein the subject experiences
sedation and/or anesthesia instantaneously.
34. The method of claim 31, wherein the compound is administered by
intravenous administration.
35. The method of claim 31, wherein the compound is administered
chronically.
36. The method of claim 31, wherein the subject is a mammal.
37. The method of claim 36, wherein the subject is a human.
38. The method of claim 31, wherein the compound is administered in
combination with another therapeutic agent.
39. A method for treating seizure in a subject, comprising
administering to the subject an effective amount of a compound of
the Formula (I): ##STR00069## or a pharmaceutically acceptable salt
thereof, wherein: A is aryl, heterocyclyl or heteroaryl; R.sup.1 is
C.sub.1-6 alkyl; R.sup.2a is C.sub.1-6 alkyl; R.sup.2b is hydrogen
or C.sub.1-6 alkyl; or R.sup.2a and R.sup.2b are joined to form an
oxo (.dbd.O) group; or R.sup.2a and R.sup.2b together with the
carbon atom to which they are attached form a ring; R.sup.3 is
absent or hydrogen; and represents a single or double bond, wherein
when one of is a double bond, the other is a single bond; and when
one of the is a double bond, R.sup.3 is absent.
40. A method for treating epilepsy or status or status epilepticus
in a subject, the method comprising administering to the subject an
effective amount of a compound of the Formula (I): ##STR00070## or
a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring; R.sup.3 is absent or hydrogen; and
represents a single or double bond, wherein when one of is a double
bond, the other is a single bond; and when one of the is a double
bond, R.sup.3 is absent.
41. A method for treating disorders related to GABA function in a
subject in need thereof, the method comprising administering to the
subject a therapeutically effective amount of a compound or
pharmaceutical composition comprising a compound of Formula (I):
##STR00071## or a pharmaceutically acceptable salt thereof,
wherein: A is aryl, heterocyclyl or heteroaryl; R.sup.1 is
C.sub.1-6 alkyl; R.sup.2a is C.sub.1-6 alkyl; R.sup.2b is hydrogen
or C.sub.1-6 alkyl; or R.sup.2a and R.sup.2b are joined to form an
oxo (.dbd.O) group; or R.sup.2a and R.sup.2b together with the
carbon atom to which they are attached form a ring; R.sup.3 is
absent or hydrogen; and represents a single or double bond, wherein
when one of is a double bond, the other is a single bond; and when
one of the is a double bond, R.sup.3 is absent.
42. A method for treating a CNS-related disorder in a subject in
need thereof, comprising administering to the subject an effective
amount a compound of Formula (I): ##STR00072## or a
pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring; R.sup.3 is absent or hydrogen; and
represents a single or double bond, wherein when one of is a double
bond, the other is a single bond; and when one of the is a double
bond, R.sup.3 is absent.
43. The method of claim 42, wherein the CNS-related disorder is a
sleep disorder, a mood disorder, a schizophrenia spectrum disorder,
a convulsive disorder, a disorder of memory and/or cognition, a
movement disorder, a personality disorder, autism spectrum
disorder, pain, traumatic brain injury, a vascular disease, a
substance abuse disorder and/or withdrawal syndrome, or
tinnitus.
44. The method of claim 42, wherein the compound is administered
orally.
45. The method of claim 42, wherein the compound is administered
intramuscularly.
46. The method of claim 42, wherein the subject is a subject with
Rett syndrome, Fragile X syndrome, or Angelman syndrome.
47. The method of claim 42, wherein the CNS-related disorder is a
sleep disorder, an eating disorder, a mood disorder, a
schizophrenia spectrum disorder, a convulsive disorder, a disorder
of memory and/or cognition, a movement disorder, a personality
disorder, autism spectrum disorder, pain, traumatic brain injury, a
vascular disease, a substance abuse disorder and/or withdrawal
syndrome, or tinnitus.
48. The method of claim 42, wherein the CNS-related disorder is
depression.
49. The method of claim 42, wherein the CNS-related disorder is
tremor.
50. The method of claim 42, wherein the CNS-related disorder is an
eating disorder.
51. A kit comprising a solid composition comprising a compound of
Formula (I): ##STR00073## or a pharmaceutically acceptable salt
thereof, wherein: A is aryl, heterocyclyl or heteroaryl; R.sup.1 is
C.sub.1-6 alkyl; R.sup.2a is C.sub.1-6 alkyl; R.sup.2b is hydrogen
or C.sub.1-6 alkyl; or R.sup.2a and R.sup.2b are joined to form an
oxo (.dbd.O) group; or R.sup.2a and R.sup.2b together with the
carbon atom to which they are attached form a ring; R.sup.3 is
absent or hydrogen; and represents a single or double bond, wherein
when one of is a double bond, the other is a single bond; and when
one of the is a double bond, R.sup.3 is absent; and a sterile
diluent.
52. A pharmaceutically acceptable salt of a compound of claim 1,
wherein the compound is selected from: ##STR00074## ##STR00075##
##STR00076## ##STR00077##
Description
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 62/064,957, filed Oct. 16, 2014, the entire
contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Brain excitability is defined as the level of arousal of an
animal, a continuum that ranges from coma to convulsions, and is
regulated by various neurotransmitters. In general,
neurotransmitters are responsible for regulating the conductance of
ions across neuronal membranes. At rest, the neuronal membrane
possesses a potential (or membrane voltage) of approximately -70
mV, the cell interior being negative with respect to the cell
exterior. The potential (voltage) is the result of ion (K.sup.+,
Na.sup.+, Cl.sup.-, organic anions) balance across the neuronal
semipermeable membrane. Neurotransmitters are stored in presynaptic
vesicles and are released under the influence of neuronal action
potentials. When released into the synaptic cleft, an excitatory
chemical transmitter such as acetylcholine will cause membrane
depolarization, e.g., a change of potential from -70 mV to -50 mV.
This effect is mediated by postsynaptic nicotinic receptors which
are stimulated by acetylcholine to increase membrane permeability
to Na.sup.+ ions. The reduced membrane potential stimulates
neuronal excitability in the form of a postsynaptic action
potential.
[0003] In the case of the GABA receptor complex (GRC), the effect
on brain excitability is mediated by GABA, a neurotransmitter. GABA
has a profound influence on overall brain excitability because up
to 40% of the neurons in the brain utilize GABA as a
neurotransmitter. GABA regulates the excitability of individual
neurons by regulating the conductance of chloride ions across the
neuronal membrane. GABA interacts with its recognition site on the
GRC to facilitate the flow of chloride ions down an electrochemical
gradient of the GRC into the cell. An intracellular increase in the
levels of this anion causes hyperpolarization of the transmembrane
potential, rendering the neuron less susceptible to excitatory
inputs, i.e., reduced neuron excitability. In other words, the
higher the chloride ion concentration in the neuron, the lower the
brain excitability and level of arousal.
[0004] It is well-documented that the GRC is responsible for the
mediation of anxiety, seizure activity, and sedation. Thus, GABA
and drugs that act like GABA or facilitate the effects of GABA
(e.g., the therapeutically useful barbiturates and benzodiazepines
(BZs), such as Valium.RTM.) produce their therapeutically useful
effects by interacting with specific regulatory sites on the GRC.
Accumulated evidence has now indicated that in addition to the
benzodiazepine and barbiturate binding site, the GRC contains a
distinct site for neuroactive steroids. See, e.g., Lan, N. C. et
al., Neurochem. Res. (1991) 16:347-356.
[0005] Neuroactive steroids can occur endogenously. The most potent
endogenous neuroactive steroids are 3.alpha.-hydroxy-5-reduced
pregnan-20-one and 3.alpha.-21-dihydroxy-5-reduced pregnan-20-one,
metabolites of hormonal steroids progesterone and
deoxycorticosterone, respectively. The ability of these steroid
metabolites to alter brain excitability was recognized in 1986
(Majewska, M. D. et al., Science 232:1004-1007 (1986); Harrison, N.
L. et al., J Pharmacol. Exp. Ther. 241:346-353 (1987)).
[0006] The ovarian hormone progesterone and its metabolites have
been demonstrated to have profound effects on brain excitability
(Backstrom, T. et al., Acta Obstet. Gynecol. Scand. Suppl.
130:19-24 (1985); Pfaff, D. W and McEwen, B. S., Science
219:808-814 (1983); Gyermek et al., J Med Chem. 11: 117 (1968);
Lambert, J. et al., Trends Pharmacol. Sci. 8:224-227 (1987)). The
levels of progesterone and its metabolites vary with the phases of
the menstrual cycle. It has been well documented that the levels of
progesterone and its metabolites decrease prior to the onset of
menses. The monthly recurrence of certain physical symptoms prior
to the onset of menses has also been well documented. These
symptoms, which have become associated with premenstrual syndrome
(PMS), include stress, anxiety, and migraine headaches (Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy, 2nd edition,
Chicago Yearbook, Chicago (1984)). Subjects with PMS have a monthly
recurrence of symptoms that are present in premenses and absent in
postmenses.
[0007] In a similar fashion, a reduction in progesterone has also
been temporally correlated with an increase in seizure frequency in
female epileptics, i.e., catamenial epilepsy (Laidlaw, J., Lancet,
1235-1237 (1956)). A more direct correlation has been observed with
a reduction in progesterone metabolites (Rosciszewska et al., J.
Neurol. Neurosurg. Psych. 49:47-51 (1986)). In addition, for
subjects with primary generalized petit mal epilepsy, the temporal
incidence of seizures has been correlated with the incidence of the
symptoms of premenstrual syndrome (Backstrom, T. et al., J.
Psychosom. Obstet. Gynaecol. 2:8-20 (1983)). The steroid
deoxycorticosterone has been found to be effective in treating
subjects with epileptic spells correlated with their menstrual
cycles (Aird, R. B. and Gordan, G., J. Amer. Med. Soc. 145:715-719
(1951)).
[0008] A syndrome also related to low progesterone levels is
postnatal depression (PND). Immediately after birth, progesterone
levels decrease dramatically leading to the onset of PND. The
symptoms of PND range from mild depression to psychosis requiring
hospitalization. PND is also associated with severe anxiety and
irritability. PND-associated depression is not amenable to
treatment by classic antidepressants, and women experiencing PND
show an increased incidence of PMS (Dalton, K., Premenstrual
Syndrome and Progesterone Therapy, 2nd edition, Chicago Yearbook,
Chicago (1984)).
[0009] Collectively, these observations imply a crucial role for
progesterone and deoxycorticosterone and more specifically their
metabolites in the homeostatic regulation of brain excitability,
which is manifested as an increase in seizure activity or symptoms
associated with catamenial epilepsy, PMS, and PND. The correlation
between reduced levels of progesterone and the symptoms associated
with PMS, PND, and catamenial epilepsy (Backstrom, T. et al., J
Psychosom. Obstet. Gynaecol. 2:8-20 (1983)); Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy, 2nd edition,
Chicago Yearbook, Chicago (1984)) has prompted the use of
progesterone in their treatment (Mattson et al.,
"Medroxyprogesterone therapy of catamenial epilepsy," in Advances
in Epileptology: XVth Epilepsy International Symposium, Raven
Press, New York (1984), pp. 279-282, and Dalton, K., Premenstrual
Syndrome and Progesterone Therapy, 2nd edition, Chicago Yearbook,
Chicago (1984)). However, progesterone is not consistently
effective in the treatment of the aforementioned syndromes. For
example, no dose-response relationship exists for progesterone in
the treatment of PMS (Maddocks et al., Obstet. Gynecol. 154:573-581
(1986); Dennerstein et al., Brit. Med J 290:16-17 (1986)).
[0010] New and improved neuroactive steroids are needed that act as
modulating agents for brain excitability, as well as agents for the
prevention and treatment of CNS-related diseases. The compounds,
compositions, and methods described herein are directed toward this
end.
SUMMARY OF THE INVENTION
[0011] Provided herein are C21-substituted neuroactive steroids
designed, for example, to act as GABA modulators. In certain
embodiments, such compounds are envisioned to be useful as
therapeutic agents for the inducement of anesthesia and/or sedation
in a subject. In some embodiments, such compounds are envisioned to
be useful as therapeutic agents for treating a CNS-related disorder
(e.g., sleep disorder, a mood disorder such as depression, a
schizophrenia spectrum disorder, a convulsive disorder, a disorder
of memory and/or cognition, a movement disorder, a personality
disorder, autism spectrum disorder, pain, traumatic brain injury, a
vascular disease, a substance abuse disorder and/or withdrawal
syndrome, or tinnitus) in a subject in need (e.g., a subject with
Rett syndrome, Fragile X syndrome, or Angelman syndrome).
[0012] In one aspect, provided is a compound of Formula (I):
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0013] In some embodiments, R.sup.1 is substituted or unsubstituted
C.sub.1-6 alkyl (e.g., haloalkyl). In some embodiments, R.sup.1 is
methyl or CF.sub.3.
[0014] In some embodiments, R.sup.2a is substituted or
unsubstituted C.sub.1-6 alkyl. In some embodiments, R.sup.2a is
methyl. In some embodiments, R.sup.2b is hydrogen. In some
embodiments, R.sup.2b is substituted or unsubstituted C.sub.1-6
alkyl. In some embodiments, R.sup.2a is methyl. In some
embodiments, R.sup.2a is methyl and R.sup.2b is hydrogen.
[0015] In some embodiments, R.sup.3 is absent. In some embodiments,
R.sup.3 is hydrogen.
[0016] In some embodiments, represents a single bond. In some
embodiments, one of represents a double bond and the other
represents a single bond.
[0017] In some embodiments, the compound of Formula (I) is a
compound of Formula (II) or Formula (III):
##STR00003##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, and R.sup.2b are defined as for Formula (I).
[0018] In some embodiments, the compound of Formula (II) is a
compound of Formula (II-a) or Formula (II-b):
##STR00004##
or a pharmaceutically acceptable salt thereof, wherein A and
R.sup.1 are defined as for Formula (I).
[0019] In some embodiments, the compound of Formula (III) is a
compound of Formula (III-a) or Formula (III-b):
##STR00005##
or a pharmaceutically acceptable salt thereof, wherein A and
R.sup.1 are defined as for Formula (I).
[0020] In some embodiments, A is heterocyclyl or heteroaryl (e.g.,
nitrogen-containing heterocyclyl or a nitrogen-containing
heteroaryl). In some embodiments, A is monocyclic or bicyclic. In
some embodiments, A is substituted with at least one R.sup.A,
wherein R.sup.A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, C.sub.1-6 haloalkyl, halogen, cyano,
--OR.sup.A6, --C(.dbd.O)OR.sup.A6, --SR.sup.B6,
--S(.dbd.O)R.sup.B6, or S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6
is hydrogen or C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, or C.sub.1-6 haloalkyl, and R.sup.B6
is C.sub.1-6 alkyl or C.sub.3-6 carbocylyl. In some embodiments,
R.sup.A is C.sub.1-6 alkyl, halogen, or cyano. In some embodiments,
A is substituted with 1-3 instances of R.sup.A.
[0021] In another aspect, provided is a compound of the Formula
(IV):
##STR00006##
or a pharmaceutically acceptable salt thereof wherein A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
R.sup.A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 carbocylyl, C.sub.1-6 haloalkyl, halogen, cyano,
--OR.sup.A6, --C(.dbd.O)OR.sup.A6, --SR.sup.B6,
--S(.dbd.O)R.sup.B6, or S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6
is hydrogen or C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, or C.sub.1-6 haloalkyl, and R.sup.B6
is C.sub.1-6 alkyl or C.sub.3-6 carbocylyl; n is 0, 1, 2 or 3; and
represents a single or double bond, wherein when one of is a double
bond, the other is a single bond; and when one of the is a double
bond, R.sup.3 is absent.
[0022] In some embodiments, R.sup.1 is substituted or unsubstituted
C.sub.1-6 alkyl (e.g., haloalkyl). In some embodiments, R.sup.1 is
methyl or CF.sub.3.
[0023] In some embodiments, R.sup.2a is substituted or
unsubstituted C.sub.1-6 alkyl. In some embodiments, R.sup.2a is
methyl. In some embodiments, R.sup.2b is hydrogen. In some
embodiments, R.sup.2b is substituted or unsubstituted C.sub.1-6
alkyl. In some embodiments, R.sup.2a is methyl. In some
embodiments, R.sup.2a is methyl and R.sup.2b is hydrogen.
[0024] In some embodiments, R.sup.3 is absent. In some embodiments,
R.sup.3 is hydrogen.
[0025] In some embodiments, represents a single bond. In some
embodiments, one of represents a double bond and the other
represents a single bond.
[0026] In some embodiments, the compound of Formula (IV) is a
compound of Formula (V) or Formula (VI):
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for Formula
(IV).
[0027] In some embodiments, the compound of Formula (V) is a
compound of Formula (V-a) or Formula (V-b):
##STR00008##
or a pharmaceutically acceptable salt thereof, wherein wherein A,
R.sup.1, R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for
Formula (IV).
[0028] In some embodiments, the compound of Formula (VI) is a
compound of Formula (VI-a) or Formula (VI-b):
##STR00009##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
are defined as for Formula (I).
[0029] In some embodiments, A is selected from:
##STR00010##
[0030] In some embodiments, A is:
##STR00011##
[0031] In some embodiments, the compound is selected from:
##STR00012## ##STR00013## ##STR00014## ##STR00015##
or a pharmaceutically acceptable salt thereof.
[0032] In one aspect, provided is a pharmaceutical composition
comprising a compound of the Formula (I) and a pharmaceutically
acceptable excipient.
[0033] In one aspect, provided is a method of inducing sedation
and/or anesthesia in a subject, comprising administering to the
subject an effective amount of a compound of the Formula (I):
##STR00016##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0034] In one aspect, provided is a method of administering an
effective amount of a compound, a pharmaceutically acceptable salt
thereof, or pharmaceutical composition of a compound of the Formula
(I) to a subject in need thereof, wherein the subject experiences
sedation and/or anesthesia within two hours of administration.
[0035] In some embodiments, the subject experiences sedation and/or
anesthesia within one hour of administration. In some embodiments,
the subject experiences sedation and/or anesthesia
instantaneously.
[0036] In some embodiments, the compound is administered by
intravenous administration.
[0037] In some embodiments, the compound is administered
chronically.
[0038] In some embodiments, the subject is a mammal. In some
embodiments, the subject is a human.
[0039] In some embodiments, the compound is administered in
combination with another therapeutic agent.
[0040] In one aspect, provided is a method for treating seizure in
a subject, comprising administering to the subject an effective
amount of a compound of the Formula (I):
##STR00017##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0041] In one aspect, provided is a method for treating epilepsy or
status or status epilepticus in a subject, the method comprising
administering to the subject an effective amount of a compound of
the Formula (I):
##STR00018##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0042] In one aspect, provided is a method for treating disorders
related to GABA function in a subject in need thereof, the method
comprising administering to the subject a therapeutically effective
amount of a compound, a pharmaceutically acceptable salt thereof,
or pharmaceutical composition of a compound of Formula (I):
##STR00019##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0043] In one aspect, provided is a method for treating a
CNS-related disorder in a subject in need thereof, comprising
administering to the subject an effective amount of a compound of
the Formula (I):
##STR00020##
[0044] or a pharmaceutically acceptable salt thereof, wherein:
[0045] A is aryl, heterocyclyl or heteroaryl;
[0046] R.sup.1 is C.sub.1-6 alkyl;
[0047] R.sup.2a is C.sub.1-6 alkyl;
[0048] R.sup.2b is hydrogen or C.sub.1-6 alkyl;
[0049] or R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O)
group;
[0050] or R.sup.2a and R.sup.2b together with the carbon atom to
which they are attached form a ring (e.g., a 3-6-membered ring
(e.g., carbocycyl or heterocyclyl ring));
[0051] R.sup.3 is absent or hydrogen; and
[0052] represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0053] In some embodiments, the CNS-related disorder is a sleep
disorder, a mood disorder such as depression, a schizophrenia
spectrum disorder, a convulsive disorder, a disorder of memory
and/or cognition, a movement disorder, a personality disorder,
autism spectrum disorder, pain, traumatic brain injury, a vascular
disease, a substance abuse disorder and/or withdrawal syndrome, or
tinnitus. In some embodiments, the subject is a subject with Rett
syndrome, Fragile X syndrome, or Angelman syndrome.
[0054] In some embodiments, the compound is administered orally. In
some embodiments, the compound is administered intramuscularly.
[0055] In some embodiments, the CNS-related disorder is depression
(e.g., post-partum depression). In some embodiments, the
CNS-related disorder is tremor (e.g., essential tremor). In some
embodiments, the CNS-related disorder is an eating disorder (e.g.,
anorexia nervosa, bulimia nervosa, binge-eating disorder,
cachexia).
[0056] In another aspect, provided is a kit comprising a solid
composition comprising a compound of Formula (I):
##STR00021##
[0057] or a pharmaceutically acceptable salt thereof, wherein:
[0058] A is aryl, heterocyclyl or heteroaryl;
[0059] R.sup.1 is C.sub.1-6 alkyl;
[0060] R.sup.2a is C.sub.1-6 alkyl;
[0061] R.sup.2b is hydrogen or C.sub.1-6 alkyl;
[0062] or R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O)
group;
[0063] or R.sup.2a and R.sup.2b together with the carbon atom to
which they are attached form a ring (e.g., a 3-6-membered ring
(e.g., carbocycyl or heterocyclyl ring));
[0064] R.sup.3 is absent or hydrogen; and
[0065] represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent;
[0066] and a sterile diluent.
[0067] The present invention also provides pharmaceutical
compositions comprising a compound of the present invention and
methods of use and treatment, e.g., such as for inducing sedation
and/or anesthesia, for treating a CNS-related disorder.
[0068] Steroids of Formula (I), sub-genera thereof, and
pharmaceutically acceptable salts thereof are collectively referred
to herein as "compounds of the present invention."
[0069] In another aspect, provided is a pharmaceutical composition
comprising a compound of the present invention and a
pharmaceutically acceptable excipient. In certain embodiments, the
compound of the present invention is provided in an effective
amount in the pharmaceutical composition. In certain embodiments,
the compound of the present invention is provided in a
therapeutically effective amount. In certain embodiments, the
compound of the present invention is provided in a prophylactically
effective amount.
[0070] Compounds of the present invention as described herein, act,
in certain embodiments, as GABA modulators, e.g., effecting the
GABA.sub.A receptor in either a positive or negative manner. As
modulators of the excitability of the central nervous system (CNS),
as mediated by their ability to modulate GABA.sub.A receptor, such
compounds are expected to have CNS-activity.
[0071] Thus, in another aspect, provided are methods of treating a
CNS-related disorder in a subject in need thereof, comprising
administering to the subject an effective amount of a compound of
the present invention. In certain embodiments, the CNS-related
disorder is selected from the group consisting of a sleep disorder,
a mood disorder such as depression, a schizophrenia spectrum
disorder, a convulsive disorder, a disorder of memory and/or
cognition, a movement disorder, a personality disorder, autism
spectrum disorder, pain, traumatic brain injury, a vascular
disease, a substance abuse disorder and/or withdrawal syndrome, and
tinnitus. In certain embodiments, the compound is administered
orally, subcutaneously, intravenously, or intramuscularly. In
certain embodiments, the compound is administered chronically. In
certain embodiments, the compound is administered continuously,
e.g., by continuous intravenous infusion.
[0072] Other objects and advantages will become apparent to those
skilled in the art from a consideration of the ensuing Detailed
Description, Examples, and Claims.
Definitions
Chemical Definitions
[0073] Definitions of specific functional groups and chemical terms
are described in more detail below. The chemical elements are
identified in accordance with the Periodic Table of the Elements,
CAS version, Handbook of Chemistry and Physics, 75.sup.th Ed.,
inside cover, and specific functional groups are generally defined
as described therein. Additionally, general principles of organic
chemistry, as well as specific functional moieties and reactivity,
are described in Thomas Sorrell, Organic Chemistry, University
Science Books, Sausalito, 1999; Smith and March, March's Advanced
Organic Chemistry, 5.sup.th Edition, John Wiley & Sons, Inc.,
New York, 2001; Larock, Comprehensive Organic Transformations, VCH
Publishers, Inc., New York, 1989; and Carruthers, Some Modern
Methods of Organic Synthesis, 3.sup.rd Edition, Cambridge
University Press, Cambridge, 1987.
[0074] Compounds described herein can comprise one or more
asymmetric centers, and thus can exist in various isomeric forms,
e.g., enantiomers and/or diastereomers. For example, the compounds
described herein can be in the form of an individual enantiomer,
diastereomer or geometric isomer, or can be in the form of a
mixture of stereoisomers, including racemic mixtures and mixtures
enriched in one or more stereoisomer. Isomers can be isolated from
mixtures by methods known to those skilled in the art, including
chiral high pressure liquid chromatography (HPLC) and the formation
and crystallization of chiral salts; or preferred isomers can be
prepared by asymmetric syntheses. See, for example, Jacques et al.,
Enantiomers, Racemates and Resolutions (Wiley Interscience, New
York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel,
Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and
Wilen, Tables of Resolving Agents and Optical Resolutions p. 268
(E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind.
1972). The invention additionally encompasses compounds described
herein as individual isomers substantially free of other isomers,
and alternatively, as mixtures of various isomers.
[0075] As used herein a pure enantiomeric compound is substantially
free from other enantiomers or stereoisomers of the compound (i.e.,
in enantiomeric excess). In other words, an "S" form of the
compound is substantially free from the "R" form of the compound
and is, thus, in enantiomeric excess of the "R" form. The term
"enantiomerically pure" or "pure enantiomer" denotes that the
compound comprises more than 75% by weight, more than 80% by
weight, more than 85% by weight, more than 90% by weight, more than
91% by weight, more than 92% by weight, more than 93% by weight,
more than 94% by weight, more than 95% by weight, more than 96% by
weight, more than 97% by weight, more than 98% by weight, more than
98.5% by weight, more than 99% by weight, more than 99.2% by
weight, more than 99.5% by weight, more than 99.6% by weight, more
than 99.7% by weight, more than 99.8% by weight or more than 99.9%
by weight, of the enantiomer. In certain embodiments, the weights
are based upon total weight of all enantiomers or stereoisomers of
the compound.
[0076] In the compositions provided herein, an enantiomerically
pure compound can be present with other active or inactive
ingredients. For example, a pharmaceutical composition comprising
enantiomerically pure R-compound can comprise, for example, about
90% excipient and about 10% enantiomerically pure R-compound. In
certain embodiments, the enantiomerically pure R-compound in such
compositions can, for example, comprise, at least about 95% by
weight R-compound and at most about 5% by weight S-compound, by
total weight of the compound. For example, a pharmaceutical
composition comprising enantiomerically pure S-compound can
comprise, for example, about 90% excipient and about 10%
enantiomerically pure S-compound. In certain embodiments, the
enantiomerically pure S-compound in such compositions can, for
example, comprise, at least about 95% by weight S-compound and at
most about 5% by weight R-compound, by total weight of the
compound. In certain embodiments, the active ingredient can be
formulated with little or no excipient or carrier.
[0077] Compound described herein may also comprise one or more
isotopic substitutions. For example, H may be in any isotopic form,
including .sup.1H, .sup.2H (D or deuterium), and .sup.3H (T or
tritium); C may be in any isotopic form, including .sup.12C,
.sup.13C, and .sup.14C; O may be in any isotopic form, including
.sup.16O and .sup.18O; and the like.
[0078] The articles "a" and "an" may be used herein to refer to one
or to more than one (i.e. at least one) of the grammatical objects
of the article. By way of example "an analogue" means one analogue
or more than one analogue.
[0079] When a range of values is listed, it is intended to
encompass each value and sub-range within the range. For example
"C.sub.1-6 alkyl" is intended to encompass, C.sub.1, C.sub.2,
C.sub.3, C.sub.4, C.sub.5, C.sub.6, C.sub.1-6, C.sub.1-5,
C.sub.1-4, C.sub.1-3, C.sub.1-2, C.sub.2-6, C.sub.2-5, C.sub.2-4,
C.sub.2-3, C.sub.3-6, C.sub.3-5, C.sub.3-4, C.sub.4-6, C.sub.4-5,
and C.sub.5-6 alkyl.
[0080] The following terms are intended to have the meanings
presented therewith below and are useful in understanding the
description and intended scope of the present invention.
[0081] "Alkyl" refers to a radical of a straight-chain or branched
saturated hydrocarbon group having from 1 to 20 carbon atoms
("C.sub.1-20 alkyl"). In some embodiments, an alkyl group has 1 to
12 carbon atoms ("C.sub.1-12 alkyl"). In some embodiments, an alkyl
group has 1 to 8 carbon atoms ("C.sub.1-8 alkyl"). In some
embodiments, an alkyl group has 1 to 6 carbon atoms ("C.sub.1-6
alkyl", also referred to herein as "lower alkyl"). In some
embodiments, an alkyl group has 1 to 5 carbon atoms ("C.sub.1-5
alkyl"). In some embodiments, an alkyl group has 1 to 4 carbon
atoms ("C.sub.1-4 alkyl"). In some embodiments, an alkyl group has
1 to 3 carbon atoms ("C.sub.1-3 alkyl"). In some embodiments, an
alkyl group has 1 to 2 carbon atoms ("C.sub.1-2 alkyl"). In some
embodiments, an alkyl group has 1 carbon atom ("C.sub.1 alkyl"). In
some embodiments, an alkyl group has 2 to 6 carbon atoms
("C.sub.2-6 alkyl"). Examples of C.sub.1-6 alkyl groups include
methyl (C.sub.1), ethyl (C.sub.2), n-propyl (C.sub.3), isopropyl
(C.sub.3), n-butyl (C.sub.4), tert-butyl (C.sub.4), sec-butyl
(C.sub.4), iso-butyl (C.sub.4), n-pentyl (C.sub.5), 3-pentanyl
(C.sub.5), amyl (C.sub.5), neopentyl (C.sub.5), 3-methyl-2-butanyl
(C.sub.5), tertiary amyl (C.sub.5), and n-hexyl (C.sub.6).
Additional examples of alkyl groups include n-heptyl (C.sub.7),
n-octyl (C.sub.8) and the like. Unless otherwise specified, each
instance of an alkyl group is independently optionally substituted,
i.e., unsubstituted (an "unsubstituted alkyl") or substituted (a
"substituted alkyl") with one or more substituents; e.g., for
instance from 1 to 5 substituents, 1 to 3 substituents, or 1
substituent. In certain embodiments, the alkyl group is
unsubstituted C.sub.1-10 alkyl (e.g., --CH.sub.3). In certain
embodiments, the alkyl group is substituted C.sub.1-10 alkyl.
Common alkyl abbreviations include Me (--CH.sub.3), Et
(--CH.sub.2CH.sub.3), iPr (--CH(CH.sub.3).sub.2), nPr
(--CH.sub.2CH.sub.2CH.sub.3), n-Bu
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), or i-Bu
(--CH.sub.2CH(CH.sub.3).sub.2).
[0082] "Alkenyl" refers to a radical of a straight-chain or
branched hydrocarbon group having from 2 to 20 carbon atoms, one or
more carbon-carbon double bonds, and no triple bonds ("C.sub.2-20
alkenyl"). In some embodiments, an alkenyl group has 2 to 10 carbon
atoms ("C.sub.2-10 alkenyl"). In some embodiments, an alkenyl group
has 2 to 8 carbon atoms ("C.sub.2-8 alkenyl"). In some embodiments,
an alkenyl group has 2 to 6 carbon atoms ("C.sub.2-6 alkenyl"). In
some embodiments, an alkenyl group has 2 to 5 carbon atoms
("C.sub.2-5 alkenyl"). In some embodiments, an alkenyl group has 2
to 4 carbon atoms ("C.sub.2-4 alkenyl"). In some embodiments, an
alkenyl group has 2 to 3 carbon atoms ("C.sub.2-3 alkenyl"). In
some embodiments, an alkenyl group has 2 carbon atoms ("C.sub.2
alkenyl"). The one or more carbon-carbon double bonds can be
internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
Examples of C.sub.2-4 alkenyl groups include ethenyl (C.sub.2),
1-propenyl (C.sub.3), 2-propenyl (C.sub.3), 1-butenyl (C.sub.4),
2-butenyl (C.sub.4), butadienyl (C.sub.4), and the like. Examples
of C.sub.2-6 alkenyl groups include the aforementioned C.sub.2-4
alkenyl groups as well as pentenyl (C.sub.5), pentadienyl
(C.sub.5), hexenyl (C.sub.6), and the like. Additional examples of
alkenyl include heptenyl (C.sub.7), octenyl (C.sub.8), octatrienyl
(C.sub.8), and the like. Unless otherwise specified, each instance
of an alkenyl group is independently optionally substituted, i.e.,
unsubstituted (an "unsubstituted alkenyl") or substituted (a
"substituted alkenyl") with one or more substituents e.g., for
instance from 1 to 5 substituents, 1 to 3 substituents, or 1
substituent. In certain embodiments, the alkenyl group is
unsubstituted C.sub.2-10 alkenyl. In certain embodiments, the
alkenyl group is substituted C.sub.2-10 alkenyl.
[0083] "Alkynyl" refers to a radical of a straight-chain or
branched hydrocarbon group having from 2 to 20 carbon atoms, one or
more carbon-carbon triple bonds, and optionally one or more double
bonds ("C.sub.2-20 alkynyl"). In some embodiments, an alkynyl group
has 2 to 10 carbon atoms ("C.sub.2-10 alkynyl"). In some
embodiments, an alkynyl group has 2 to 8 carbon atoms ("C.sub.2-8
alkynyl"). In some embodiments, an alkynyl group has 2 to 6 carbon
atoms ("C.sub.2-6 alkynyl"). In some embodiments, an alkynyl group
has 2 to 5 carbon atoms ("C.sub.2-5 alkynyl"). In some embodiments,
an alkynyl group has 2 to 4 carbon atoms ("C.sub.2-4 alkynyl"). In
some embodiments, an alkynyl group has 2 to 3 carbon atoms
("C.sub.2-3 alkynyl"). In some embodiments, an alkynyl group has 2
carbon atoms ("C.sub.2 alkynyl"). The one or more carbon-carbon
triple bonds can be internal (such as in 2-butynyl) or terminal
(such as in 1-butynyl). Examples of C.sub.2-4 alkynyl groups
include, without limitation, ethynyl (C.sub.2), 1-propynyl
(C.sub.3), 2-propynyl (C.sub.3), 1-butynyl (C.sub.4), 2-butynyl
(C.sub.4), and the like. Examples of C.sub.2-6 alkenyl groups
include the aforementioned C.sub.2-4 alkynyl groups as well as
pentynyl (C.sub.5), hexynyl (C.sub.6), and the like. Additional
examples of alkynyl include heptynyl (C.sub.7), octynyl (C.sub.8),
and the like. Unless otherwise specified, each instance of an
alkynyl group is independently optionally substituted, i.e.,
unsubstituted (an "unsubstituted alkynyl") or substituted (a
"substituted alkynyl") with one or more substituents; e.g., for
instance from 1 to 5 substituents, 1 to 3 substituents, or 1
substituent. In certain embodiments, the alkynyl group is
unsubstituted C.sub.2-10 alkynyl. In certain embodiments, the
alkynyl group is substituted C.sub.2-10 alkynyl.
[0084] "Aryl" refers to a radical of a monocyclic or polycyclic
(e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g.,
having 6, 10, or 14.pi. electrons shared in a cyclic array) having
6-14 ring carbon atoms and zero heteroatoms provided in the
aromatic ring system ("C.sub.6-14 aryl"). In some embodiments, an
aryl group has six ring carbon atoms ("C.sub.6 aryl"; e.g.,
phenyl). In some embodiments, an aryl group has ten ring carbon
atoms ("C.sub.10 aryl"; e.g., naphthyl such as 1-naphthyl and
2-naphthyl). In some embodiments, an aryl group has fourteen ring
carbon atoms ("C.sub.14 aryl"; e.g., anthracyl). "Aryl" also
includes ring systems wherein the aryl ring, as defined above, is
fused with one or more carbocyclyl or heterocyclyl groups wherein
the radical or point of attachment is on the aryl ring, and in such
instances, the number of carbon atoms continue to designate the
number of carbon atoms in the aryl ring system. Aryl groups
include, but are not limited to, phenyl, naphthyl, indenyl, and
tetrahydronaphthyl. Unless otherwise specified, each instance of an
aryl group is independently optionally substituted, i.e.,
unsubstituted (an "unsubstituted aryl") or substituted (a
"substituted aryl") with one or more substituents. In certain
embodiments, the aryl group is unsubstituted C.sub.6-14 aryl. In
certain embodiments, the aryl group is substituted C.sub.6-14
aryl.
[0085] In certain embodiments, an aryl group substituted with one
or more of groups selected from halo, C.sub.1-C.sub.8 alkyl,
C.sub.1-C.sub.8 haloalkyl, cyano, hydroxy, C.sub.1-C.sub.8 alkoxy,
and amino.
[0086] Examples of representative substituted aryls include the
following
##STR00022##
wherein one of R.sup.56 and R.sup.57 may be hydrogen and at least
one of R.sup.56 and R.sup.57 is each independently selected from
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 haloalkyl, 4-10 membered
heterocyclyl, alkanoyl, C.sub.1-C.sub.8 alkoxy, heteroaryloxy,
alkylamino, arylamino, heteroarylamino, NR.sup.58COR.sup.59,
NR.sup.58SOR.sup.59 NR.sup.58SO.sub.2R.sup.59, COOalkyl, COOaryl,
CONR.sup.58R.sup.59, CONR.sup.58OR.sup.59, NR.sup.58R.sup.59,
SO.sub.2NR.sup.58R.sup.59, S-alkyl, SOalkyl, SO.sub.2alkyl, Saryl,
SOaryl, SO.sub.2aryl; or R.sup.56 and R.sup.57 may be joined to
form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms,
optionally containing one or more heteroatoms selected from the
group N, O, or S. R.sup.60 and R.sup.61 are independently hydrogen,
C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.4 haloalkyl, C.sub.3-C.sub.10
cycloalkyl, 4-10 membered heterocyclyl, C.sub.6-C.sub.10 aryl,
substituted C.sub.6-C.sub.10 aryl, 5-10 membered heteroaryl, or
substituted 5-10 membered heteroaryl.
[0087] Other representative aryl groups having a fused heterocyclyl
group include the following:
##STR00023##
wherein each W is selected from C(R.sup.66).sub.2, NR.sup.66, O,
and S; and each Y is selected from carbonyl, NR.sup.66, O and S;
and R.sup.66 is independently hydrogen, C.sub.1-C.sub.8 alkyl,
C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, and 5-10 membered heteroaryl.
[0088] "Halo" or "halogen," independently or as part of another
substituent, mean, unless otherwise stated, a fluorine (F),
chlorine (Cl), bromine (Br), or iodine (I) atom. The term "halide"
by itself or as part of another substituent, refers to a fluoride,
chloride, bromide, or iodide atom. In certain embodiments, the halo
group is either fluorine or chlorine.
[0089] "Haloalkyl" and "haloalkoxy" can include alkyl and alkoxy
structures that are substituted with one or more halo groups or
with combinations thereof. For example, the terms "fluoroalkyl" and
"fluoroalkoxy" include haloalkyl and haloalkoxy groups,
respectively, in which the halo is fluorine.
[0090] "Heteroaryl" refers to a radical of a 5-10 membered
monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or
10.pi. electrons shared in a cyclic array) having ring carbon atoms
and 1-4 ring heteroatoms provided in the aromatic ring system,
wherein each heteroatom is independently selected from nitrogen,
oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl
groups that contain one or more nitrogen atoms, the point of
attachment can be a carbon or nitrogen atom, as valency permits.
Heteroaryl bicyclic ring systems can include one or more
heteroatoms in one or both rings. "Heteroaryl" includes ring
systems wherein the heteroaryl ring, as defined above, is fused
with one or more carbocyclyl or heterocyclyl groups wherein the
point of attachment is on the heteroaryl ring, and in such
instances, the number of ring members continue to designate the
number of ring members in the heteroaryl ring system. "Heteroaryl"
also includes ring systems wherein the heteroaryl ring, as defined
above, is fused with one or more aryl groups wherein the point of
attachment is either on the aryl or heteroaryl ring, and in such
instances, the number of ring members designates the number of ring
members in the fused (aryl/heteroaryl) ring system. Bicyclic
heteroaryl groups wherein one ring does not contain a heteroatom
(e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of
attachment can be on either ring, i.e., either the ring bearing a
heteroatom (e.g., 2-indolyl) or the ring that does not contain a
heteroatom (e.g., 5-indolyl).
[0091] In some embodiments, a heteroaryl group is a 5-10 membered
aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms provided in the aromatic ring system, wherein each
heteroatom is independently selected from nitrogen, oxygen, and
sulfur ("5-10 membered heteroaryl"). In some embodiments, a
heteroaryl group is a 5-8 membered aromatic ring system having ring
carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring
system, wherein each heteroatom is independently selected from
nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some
embodiments, a heteroaryl group is a 5-6 membered aromatic ring
system having ring carbon atoms and 1-4 ring heteroatoms provided
in the aromatic ring system, wherein each heteroatom is
independently selected from nitrogen, oxygen, and sulfur ("5-6
membered heteroaryl"). In some embodiments, the 5-6 membered
heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen,
and sulfur. In some embodiments, the 5-6 membered heteroaryl has
1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In
some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom
selected from nitrogen, oxygen, and sulfur. Unless otherwise
specified, each instance of a heteroaryl group is independently
optionally substituted, i.e., unsubstituted (an "unsubstituted
heteroaryl") or substituted (a "substituted heteroaryl") with one
or more substituents. In certain embodiments, the heteroaryl group
is unsubstituted 5-14 membered heteroaryl. In certain embodiments,
the heteroaryl group is substituted 5-14 membered heteroaryl.
[0092] Exemplary 5-membered heteroaryl groups containing one
heteroatom include, without limitation, pyrrolyl, furanyl and
thiophenyl. Exemplary 5-membered heteroaryl groups containing two
heteroatoms include, without limitation, imidazolyl, pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary
5-membered heteroaryl groups containing three heteroatoms include,
without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
Exemplary 5-membered heteroaryl groups containing four heteroatoms
include, without limitation, tetrazolyl. Exemplary 6-membered
heteroaryl groups containing one heteroatom include, without
limitation, pyridinyl. Exemplary 6-membered heteroaryl groups
containing two heteroatoms include, without limitation,
pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered
heteroaryl groups containing three or four heteroatoms include,
without limitation, triazinyl and tetrazinyl, respectively.
Exemplary 7-membered heteroaryl groups containing one heteroatom
include, without limitation, azepinyl, oxepinyl, and thiepinyl.
Exemplary 5,6-bicyclic heteroaryl groups include, without
limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl,
benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl,
benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl,
benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and
purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without
limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl,
cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0093] Examples of representative heteroaryls include the following
formulae:
##STR00024##
wherein each Y is selected from carbonyl, N, NR.sup.65, O, and S;
and R.sup.65 is independently hydrogen, C.sub.1-C.sub.8 alkyl,
C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, and 5-10 membered heteroaryl.
[0094] "Carbocyclyl" or "carbocyclic" refers to a radical of a
non-aromatic cyclic hydrocarbon group having from 3 to 10 ring
carbon atoms ("C.sub.3-10 carbocyclyl") and zero heteroatoms in the
non-aromatic ring system. In some embodiments, a carbocyclyl group
has 3 to 8 ring carbon atoms ("C.sub.3-8 carbocyclyl"). In some
embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms
("C.sub.3-6 carbocyclyl"). In some embodiments, a carbocyclyl group
has 3 to 6 ring carbon atoms ("C.sub.3-6 carbocyclyl"). In some
embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms
("C.sub.5-10 carbocyclyl"). Exemplary C.sub.3-6 carbocyclyl groups
include, without limitation, cyclopropyl (C.sub.3), cyclopropenyl
(C.sub.3), cyclobutyl (C.sub.4), cyclobutenyl (C.sub.4),
cyclopentyl (C.sub.5), cyclopentenyl (C.sub.5), cyclohexyl
(C.sub.6), cyclohexenyl (C.sub.6), cyclohexadienyl (C.sub.6), and
the like. Exemplary C.sub.3-8 carbocyclyl groups include, without
limitation, the aforementioned C.sub.3-6 carbocyclyl groups as well
as cycloheptyl (C.sub.7), cycloheptenyl (C.sub.7), cycloheptadienyl
(C.sub.7), cycloheptatrienyl (C.sub.7), cyclooctyl (C.sub.8),
cyclooctenyl (C.sub.8), bicyclo[2.2.1]heptanyl (C.sub.7),
bicyclo[2.2.2]octanyl (C.sub.8), and the like. Exemplary C.sub.3-10
carbocyclyl groups include, without limitation, the aforementioned
C.sub.3-8 carbocyclyl groups as well as cyclononyl (C.sub.9),
cyclononenyl (C.sub.9), cyclodecyl (C.sub.10), cyclodecenyl
(C.sub.10), octahydro-1H-indenyl (C.sub.9), decahydronaphthalenyl
(C.sub.10), spiro[4.5]decanyl (C.sub.10), and the like. As the
foregoing examples illustrate, in certain embodiments, the
carbocyclyl group is either monocyclic ("monocyclic carbocyclyl")
or contain a fused, bridged or spiro ring system such as a bicyclic
system ("bicyclic carbocyclyl") and can be saturated or can be
partially unsaturated. "Carbocyclyl" also includes ring systems
wherein the carbocyclyl ring, as defined above, is fused with one
or more aryl or heteroaryl groups wherein the point of attachment
is on the carbocyclyl ring, and in such instances, the number of
carbons continue to designate the number of carbons in the
carbocyclic ring system. Unless otherwise specified, each instance
of a carbocyclyl group is independently optionally substituted,
i.e., unsubstituted (an "unsubstituted carbocyclyl") or substituted
(a "substituted carbocyclyl") with one or more substituents. In
certain embodiments, the carbocyclyl group is unsubstituted
C.sub.3-10 carbocyclyl. In certain embodiments, the carbocyclyl
group is a substituted C.sub.3-10 carbocyclyl.
[0095] In some embodiments, "carbocyclyl" is a monocyclic,
saturated carbocyclyl group having from 3 to 10 ring carbon atoms
("C.sub.3-10 cycloalkyl"). In some embodiments, a cycloalkyl group
has 3 to 8 ring carbon atoms ("C.sub.3-8 cycloalkyl"). In some
embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms
("C.sub.3-6 cycloalkyl"). In some embodiments, a cycloalkyl group
has 5 to 6 ring carbon atoms ("C.sub.5-6 cycloalkyl"). In some
embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms
("C.sub.5-10 cycloalkyl"). Examples of C.sub.5-6 cycloalkyl groups
include cyclopentyl (C.sub.5) and cyclohexyl (C.sub.5). Examples of
C.sub.3-6 cycloalkyl groups include the aforementioned C.sub.5-6
cycloalkyl groups as well as cyclopropyl (C.sub.3) and cyclobutyl
(C.sub.4). Examples of C.sub.3-8 cycloalkyl groups include the
aforementioned C.sub.3-6 cycloalkyl groups as well as cycloheptyl
(C.sub.7) and cyclooctyl (C.sub.8). Unless otherwise specified,
each instance of a cycloalkyl group is independently unsubstituted
(an "unsubstituted cycloalkyl") or substituted (a "substituted
cycloalkyl") with one or more substituents. In certain embodiments,
the cycloalkyl group is unsubstituted C.sub.3-10 cycloalkyl. In
certain embodiments, the cycloalkyl group is substituted C.sub.3-10
cycloalkyl.
[0096] "Heterocyclyl" or "heterocyclic" refers to a radical of a 3-
to 10-membered non-aromatic ring system having ring carbon atoms
and 1 to 4 ring heteroatoms, wherein each heteroatom is
independently selected from nitrogen, oxygen, sulfur, boron,
phosphorus, and silicon ("3-10 membered heterocyclyl"). In
heterocyclyl groups that contain one or more nitrogen atoms, the
point of attachment can be a carbon or nitrogen atom, as valency
permits. A heterocyclyl group can either be monocyclic ("monocyclic
heterocyclyl") or a fused, bridged or spiro ring system such as a
bicyclic system ("bicyclic heterocyclyl"), and can be saturated or
can be partially unsaturated. Heterocyclyl bicyclic ring systems
can include one or more heteroatoms in one or both rings.
"Heterocyclyl" also includes ring systems wherein the heterocyclyl
ring, as defined above, is fused with one or more carbocyclyl
groups wherein the point of attachment is either on the carbocyclyl
or heterocyclyl ring, or ring systems wherein the heterocyclyl
ring, as defined above, is fused with one or more aryl or
heteroaryl groups, wherein the point of attachment is on the
heterocyclyl ring, and in such instances, the number of ring
members continue to designate the number of ring members in the
heterocyclyl ring system. Unless otherwise specified, each instance
of heterocyclyl is independently optionally substituted, i.e.,
unsubstituted (an "unsubstituted heterocyclyl") or substituted (a
"substituted heterocyclyl") with one or more substituents. In
certain embodiments, the heterocyclyl group is unsubstituted 3-10
membered heterocyclyl. In certain embodiments, the heterocyclyl
group is substituted 3-10 membered heterocyclyl.
[0097] In some embodiments, a heterocyclyl group is a 5-10 membered
non-aromatic ring system having ring carbon atoms and 1-4 ring
heteroatoms, wherein each heteroatom is independently selected from
nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("5-10
membered heterocyclyl"). In some embodiments, a heterocyclyl group
is a 5-8 membered non-aromatic ring system having ring carbon atoms
and 1-4 ring heteroatoms, wherein each heteroatom is independently
selected from nitrogen, oxygen, and sulfur ("5-8 membered
heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6
membered non-aromatic ring system having ring carbon atoms and 1-4
ring heteroatoms, wherein each heteroatom is independently selected
from nitrogen, oxygen, and sulfur ("5-6 membered heterocyclyl"). In
some embodiments, the 5-6 membered heterocyclyl has 1-3 ring
heteroatoms selected from nitrogen, oxygen, and sulfur. In some
embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms
selected from nitrogen, oxygen, and sulfur. In some embodiments,
the 5-6 membered heterocyclyl has one ring heteroatom selected from
nitrogen, oxygen, and sulfur.
[0098] Exemplary 3-membered heterocyclyl groups containing one
heteroatom include, without limitation, azirdinyl, oxiranyl,
thiorenyl. Exemplary 4-membered heterocyclyl groups containing one
heteroatom include, without limitation, azetidinyl, oxetanyl and
thietanyl. Exemplary 5-membered heterocyclyl groups containing one
heteroatom include, without limitation, tetrahydrofuranyl,
dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl,
pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary
5-membered heterocyclyl groups containing two heteroatoms include,
without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and
oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups
containing three heteroatoms include, without limitation,
triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary
6-membered heterocyclyl groups containing one heteroatom include,
without limitation, piperidinyl, tetrahydropyranyl,
dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl
groups containing two heteroatoms include, without limitation,
piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered
heterocyclyl groups containing two heteroatoms include, without
limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups
containing one heteroatom include, without limitation, azepanyl,
oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups
containing one heteroatom include, without limitation, azocanyl,
oxecanyl and thiocanyl. Exemplary 5-membered heterocyclyl groups
fused to a C.sub.6 aryl ring (also referred to herein as a
5,6-bicyclic heterocyclic ring) include, without limitation,
indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,
benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl
groups fused to an aryl ring (also referred to herein as a
6,6-bicyclic heterocyclic ring) include, without limitation,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0099] Particular examples of heterocyclyl groups are shown in the
following illustrative examples:
##STR00025##
wherein each W is selected from CR.sup.67, C(R.sup.67).sub.2,
NR.sup.67, O, and S; and each Y is selected from NR.sup.67, O, and
S; and R.sup.67 is independently hydrogen, C.sub.1-C.sub.8 alkyl,
C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, and 5-10-membered heteroaryl. These
heterocyclyl rings may be optionally substituted with one or more
groups selected from the group consisting of acyl, acylamino,
acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino,
substituted amino, aminocarbonyl (e.g., amido), aminocarbonylamino,
aminosulfonyl, sulfonylamino, aryl, aryloxy, azido, carboxyl,
cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, --S-alkyl,
--S-aryl, --S(O)-alkyl, --S(O)-aryl, --S(O).sub.2-alkyl, and
--S(O).sub.2-aryl. Substituting groups include carbonyl or
thiocarbonyl which provide, for example, lactam and urea
derivatives.
[0100] "Acyl" refers to a radical --C(O)R.sup.20, where R.sup.20 is
hydrogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl, as defined herein.
"Alkanoyl" is an acyl group wherein R.sup.20 is a group other than
hydrogen. Representative acyl groups include, but are not limited
to, formyl (--CHO), acetyl (--C(.dbd.O)CH.sub.3),
cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl
(--C(.dbd.O)Ph), benzylcarbonyl (--C(.dbd.O)CH.sub.2Ph),
--C(O)--C.sub.1-C.sub.8 alkyl,
--C(O)--(CH.sub.2).sub.t(C.sub.6-C.sub.10 aryl),
--C(O)--(CH.sub.2).sub.t(5-10 membered heteroaryl),
--C(O)--(CH.sub.2).sub.t(C.sub.3-C.sub.10 cycloalkyl), and
--C(O)--(CH.sub.2).sub.t(4-10 membered heterocyclyl), wherein t is
an integer from 0 to 4. In certain embodiments, R.sup.21 is
C.sub.1-C.sub.8 alkyl, substituted with halo or hydroxy; or
C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, arylalkyl, 5-10 membered heteroaryl or
heteroarylalkyl, each of which is substituted with unsubstituted
C.sub.1-C.sub.4 alkyl, halo, unsubstituted C.sub.1-C.sub.4 alkoxy,
unsubstituted C.sub.1-C.sub.4 haloalkyl, unsubstituted
C.sub.1-C.sub.4 hydroxyalkyl, or unsubstituted C.sub.1-C.sub.4
haloalkoxy or hydroxy.
[0101] "Acylamino" refers to a radical --NR.sup.22C(O)R.sup.23,
where each instance of R.sup.22 and R.sup.23 is independently
hydrogen, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl, as defined herein, or
R.sup.22 is an amino protecting group. Exemplary "acylamino" groups
include, but are not limited to, formylamino, acetylamino,
cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino,
benzoylamino and benzylcarbonylamino. Particular exemplary
"acylamino" groups are --NR.sup.24C(O)--C.sub.1-C.sub.8 alkyl,
--NR.sup.24C(O)--(CH.sub.2).sub.t(C.sub.6-C.sub.10 aryl),
--NR.sup.24C(O)--(CH.sub.2).sub.t(5-10 membered heteroaryl),
--NR.sup.24C(O)--(CH.sub.2).sub.t(C.sub.3-C.sub.10 cycloalkyl), and
--NR.sup.24C(O)--(CH.sub.2).sub.t(4-10 membered heterocyclyl),
wherein t is an integer from 0 to 4, and each R.sup.24
independently represents hydrogen or C.sub.1-C.sub.8 alkyl. In
certain embodiments, R.sup.25 is H, C.sub.1-C.sub.8 alkyl,
substituted with halo or hydroxy; C.sub.3-C.sub.10 cycloalkyl, 4-10
membered heterocyclyl, C.sub.6-C.sub.10 aryl, arylalkyl, 5-10
membered heteroaryl or heteroarylalkyl, each of which is
substituted with unsubstituted C.sub.1-C.sub.4 alkyl, halo,
unsubstituted C.sub.1-C.sub.4 alkoxy, unsubstituted C.sub.1-C.sub.4
haloalkyl, unsubstituted C.sub.1-C.sub.4 hydroxyalkyl, or
unsubstituted C.sub.1-C.sub.4 haloalkoxy or hydroxy; and R.sup.26
is H, C.sub.1-C.sub.8 alkyl, substituted with halo or hydroxy;
C.sub.3-C.sub.10 cycloalkyl, 4-10-membered heterocyclyl,
C.sub.6-C.sub.10 aryl, arylalkyl, 5-10-membered heteroaryl or
heteroarylalkyl, each of which is substituted with unsubstituted
C.sub.1-C.sub.4 alkyl, halo, unsubstituted C.sub.1-C.sub.4 alkoxy,
unsubstituted C.sub.1-C.sub.4 haloalkyl, unsubstituted
C.sub.1-C.sub.4 hydroxyalkyl, or unsubstituted C.sub.1-C.sub.4
haloalkoxy or hydroxy; provided at least one of R.sup.25 and
R.sup.26 is other than H.
[0102] "Acyloxy" refers to a radical --OC(O)R.sup.27, where
R.sup.27 is hydrogen, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl, or
substituted or unsubstituted heteroaryl, as defined herein.
Representative examples include, but are not limited to, formyl,
acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, and
benzylcarbonyl. In certain embodiments, R.sup.28 is C.sub.1-C.sub.8
alkyl, substituted with halo or hydroxy; C.sub.3-C.sub.10
cycloalkyl, 4-10-membered heterocyclyl, C.sub.6-C.sub.10 aryl,
arylalkyl, 5-10-membered heteroaryl or heteroarylalkyl, each of
which is substituted with unsubstituted C.sub.1-C.sub.4 alkyl,
halo, unsubstituted C.sub.1-C.sub.4 alkoxy, unsubstituted
C.sub.1-C.sub.4 haloalkyl, unsubstituted C.sub.1-C.sub.4
hydroxyalkyl, or unsubstituted C.sub.1-C.sub.4 haloalkoxy or
hydroxy.
[0103] "Alkoxy" refers to the group --OR.sup.29 where R.sup.29 is
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted carbocyclyl, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aryl, or substituted or
unsubstituted heteroaryl. Particular alkoxy groups are methoxy,
ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy,
n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy
groups are lower alkoxy, i.e., with between 1 and 6 carbon atoms.
Further particular alkoxy groups have between 1 and 4 carbon
atoms.
[0104] In certain embodiments, R.sup.29 is a group that has 1 or
more substituents, for instance from 1 to 5 substituents, and
particularly from 1 to 3 substituents, in particular 1 substituent,
selected from the group consisting of amino, substituted amino,
C.sub.6-C.sub.10 aryl, aryloxy, carboxyl, cyano, C.sub.3-C.sub.10
cycloalkyl, 4-10 membered heterocyclyl, halogen, 5-10 membered
heteroaryl, hydroxy, nitro, thioalkoxy, thioaryloxy, thiol,
alkyl-S(O)--, aryl-S(O)--, alkyl-S(O).sub.2-- and
aryl-S(O).sub.2--. Exemplary "substituted alkoxy" groups include,
but are not limited to, --O--(CH.sub.2).sub.t(C.sub.6-C.sub.10
aryl), --O--(CH.sub.2).sub.t(5-10 membered heteroaryl),
--O--(CH.sub.2).sub.t(C.sub.3-C.sub.10 cycloalkyl), and
--O--(CH.sub.2).sub.t(4-10 membered heterocyclyl), wherein t is an
integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or
heterocyclyl groups present, may themselves be substituted by
unsubstituted C.sub.1-C.sub.4 alkyl, halo, unsubstituted
C.sub.1-C.sub.4 alkoxy, unsubstituted C.sub.1-C.sub.4 haloalkyl,
unsubstituted C.sub.1-C.sub.4 hydroxyalkyl, or unsubstituted
C.sub.1-C.sub.4 haloalkoxy or hydroxy. Particular exemplary
`substituted alkoxy` groups are --OCF.sub.3, --OCH.sub.2CF.sub.3,
--OCH.sub.2Ph, --OCH.sub.2-cyclopropyl, --OCH.sub.2CH.sub.2OH, and
--OCH.sub.2CH.sub.2NMe.sub.2.
[0105] "Amino" refers to the radical --NH.sub.2.
[0106] "Substituted amino" refers to an amino group of the formula
--N(R.sup.38).sub.2 wherein R.sup.38 is hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted
carbocyclyl, substituted or unsubstituted heterocyclyl, substituted
or unsubstituted aryl, substituted or unsubstituted heteroaryl, or
an amino protecting group, wherein at least one of R.sup.38 is not
a hydrogen. In certain embodiments, each R.sup.38 is independently
selected from hydrogen, C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.8
alkenyl, C.sub.3-C.sub.8 alkynyl, C.sub.6-C.sub.10 aryl, 5-10
membered heteroaryl, 4-10 membered heterocyclyl, or
C.sub.3-C.sub.10 cycloalkyl; or C.sub.1-C.sub.8 alkyl, substituted
with halo or hydroxy; C.sub.3-C.sub.8 alkenyl, substituted with
halo or hydroxy; C.sub.3-C.sub.8 alkynyl, substituted with halo or
hydroxy, or --(CH.sub.2).sub.t(C.sub.6-C.sub.10 aryl),
--(CH.sub.2).sub.t(5-10 membered heteroaryl),
--(CH.sub.2).sub.t(C.sub.3-C.sub.10 cycloalkyl), or
--(CH.sub.2).sub.t(4-10 membered heterocyclyl), wherein t is an
integer between 0 and 8, each of which is substituted by
unsubstituted C.sub.1-C.sub.4 alkyl, halo, unsubstituted
C.sub.1-C.sub.4 alkoxy, unsubstituted C.sub.1-C.sub.4 haloalkyl,
unsubstituted C.sub.1-C.sub.4 hydroxyalkyl, or unsubstituted
C.sub.1-C.sub.4 haloalkoxy or hydroxy; or both R.sup.38 groups are
joined to form an alkylene group.
[0107] Exemplary "substituted amino" groups include, but are not
limited to, --NR.sup.39--C.sub.1-C.sub.8 alkyl,
--NR.sup.39--(CH.sub.2).sub.t(C.sub.6-C.sub.10 aryl),
--NR.sup.39--(CH.sub.2).sub.t(5-10 membered heteroaryl),
--NR.sup.39--(CH.sub.2).sub.t(C.sub.3-C.sub.10 cycloalkyl), and
--NR.sup.39--(CH.sub.2).sub.t(4-10 membered heterocyclyl), wherein
t is an integer from 0 to 4, for instance 1 or 2, each R.sup.39
independently represents hydrogen or C.sub.1-C.sub.8 alkyl; and any
alkyl groups present, may themselves be substituted by halo,
substituted or unsubstituted amino, or hydroxy; and any aryl,
heteroaryl, cycloalkyl, or heterocyclyl groups present, may
themselves be substituted by unsubstituted C.sub.1-C.sub.4 alkyl,
halo, unsubstituted C.sub.1-C.sub.4 alkoxy, unsubstituted
C.sub.1-C.sub.4 haloalkyl, unsubstituted C.sub.1-C.sub.4
hydroxyalkyl, or unsubstituted C.sub.1-C.sub.4 haloalkoxy or
hydroxy. For the avoidance of doubt the term `substituted amino`
includes the groups alkylamino, substituted alkylamino,
alkylarylamino, substituted alkylarylamino, arylamino, substituted
arylamino, dialkylamino, and substituted dialkylamino as defined
below. Substituted amino encompasses both monosubstituted amino and
disubstituted amino groups.
[0108] "Azido" refers to the radical --N.sub.3.
[0109] "Carbamoyl" or "amido" refers to the radical
--C(O)NH.sub.2.
[0110] "Substituted carbamoyl" or "substituted amido" refers to the
radical --C(O)N(R.sup.62).sub.2 wherein each R.sup.62 is
independently hydrogen, substituted or unsubstituted alkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted carbocyclyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or an amino protecting
group, wherein at least one of R.sup.62 is not a hydrogen. In
certain embodiments, R.sup.62 is selected from H, C.sub.1-C.sub.8
alkyl, C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, and 5-10 membered heteroaryl; or
C.sub.1-C.sub.8 alkyl substituted with halo or hydroxy; or
C.sub.3-C.sub.10 cycloalkyl, 4-10 membered heterocyclyl,
C.sub.6-C.sub.10 aryl, or 5-10 membered heteroaryl, each of which
is substituted by unsubstituted C.sub.1-C.sub.4 alkyl, halo,
unsubstituted C.sub.1-C.sub.4 alkoxy, unsubstituted C.sub.1-C.sub.4
haloalkyl, unsubstituted C.sub.1-C.sub.4 hydroxyalkyl, or
unsubstituted C.sub.1-C.sub.4 haloalkoxy or hydroxy; provided that
at least one R.sup.62 is other than H.
[0111] "Carboxy" refers to the radical --C(O)OH.
[0112] "Cyano" refers to the radical --CN.
[0113] "Hydroxy" refers to the radical --OH.
[0114] "Nitro" refers to the radical --NO.sub.2.
[0115] "Ethenyl" refers to substituted or unsubstituted
--(C.dbd.C)--. "Ethylene" refers to substituted or unsubstituted
--(C--C)--. "Ethynyl" refers to --(C.ident.C)--.
[0116] "Nitrogen-containing heterocyclyl" group means a 4- to
7-membered non-aromatic cyclic group containing at least one
nitrogen atom, for example, but without limitation, morpholine,
piperidine (e.g. 2-piperidinyl, 3-piperidinyl and 4-piperidinyl),
pyrrolidine (e.g. 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine,
pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline,
pyrazolidine, piperazine, and N-alkyl piperazines such as N-methyl
piperazine. Particular examples include azetidine, piperidone and
piperazone.
[0117] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl,
and heteroaryl groups, as defined herein, are optionally
substituted (e.g., "substituted" or "unsubstituted" alkyl,
"substituted" or "unsubstituted" alkenyl, "substituted" or
"unsubstituted" alkynyl, "substituted" or "unsubstituted"
carbocyclyl, "substituted" or "unsubstituted" heterocyclyl,
"substituted" or "unsubstituted" aryl or "substituted" or
"unsubstituted" heteroaryl group). In general, the term
"substituted", whether preceded by the term "optionally" or not,
means that at least one hydrogen present on a group (e.g., a carbon
or nitrogen atom) is replaced with a permissible substituent, e.g.,
a substituent which upon substitution results in a stable compound,
e.g., a compound which does not spontaneously undergo
transformation such as by rearrangement, cyclization, elimination,
or other reaction. Unless otherwise indicated, a "substituted"
group has a substituent at one or more substitutable positions of
the group, and when more than one position in any given structure
is substituted, the substituent is either the same or different at
each position. The term "substituted" is contemplated to include
substitution with all permissible substituents of organic
compounds, any of the substituents described herein that results in
the formation of a stable compound. The present invention
contemplates any and all such combinations in order to arrive at a
stable compound. For purposes of this invention, heteroatoms such
as nitrogen may have hydrogen substituents and/or any suitable
substituent as described herein which satisfy the valencies of the
heteroatoms and results in the formation of a stable moiety.
[0118] Exemplary carbon atom substituents include, but are not
limited to, halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H,
--SO.sub.3H, --OH, --OR.sup.aa, --ON(R.sup.bb).sub.2,
--N(R.sup.bb).sub.2, --N(R.sup.bb).sub.3.sup.+X.sup.-,
--N(OR.sup.cc)R.sup.bb, --SH, --SR.sup.aa, --SSR.sup.cc,
--C(.dbd.O)R.sup.aa, --CO.sub.2H, --CHO, --C(OR.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --OC(.dbd.O)R.sup.aa, --OCO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --OC(.dbd.O)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.O)R.sup.aa, --NR.sup.bbCO.sub.2R.sup.aa,
--NR.sup.bbC(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --OC(.dbd.NR.sup.bb)R.sup.aa,
--OC(.dbd.NR.sup.bb)OR.sup.aa,
--C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--OC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--NR.sup.bbC(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--C(.dbd.O)NR.sup.bbSO.sub.2R.sup.aa, --NR.sup.bbSO.sub.2R.sup.aa,
--SO.sub.2N(R.sup.bb).sub.2, --SO.sub.2R.sup.aa,
--SO.sub.2OR.sup.aa, --OSO.sub.2R.sup.aa, --S(.dbd.O)R.sup.aa,
--OS(.dbd.O)R.sup.aa, --Si(R.sup.aa).sub.3,
--OSi(R.sup.aa).sub.3--C(.dbd.S)N(R.sup.bb).sub.2,
--C(.dbd.O)SR.sup.aa, --C(.dbd.S)SR.sup.aa, --SC(.dbd.S)SR.sup.aa,
--SC(.dbd.O)SR.sup.aa, --OC(.dbd.O)SR.sup.aa,
--SC(.dbd.O)OR.sup.aa, --SC(.dbd.O)R.sup.aa,
--P(.dbd.O).sub.2R.sup.aa, --OP(.dbd.O).sub.2R.sup.aa,
--P(.dbd.O)(R.sup.aa).sub.2, --OP(.dbd.O)(R.sup.aa).sub.2,
--OP(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
--OP(.dbd.O).sub.2N(R.sup.bb).sub.2, --P(.dbd.O)(NR.sup.bb).sub.2,
--OP(.dbd.O)(NR.sup.bb).sub.2,
--NR.sup.bbP(.dbd.O)(OR.sup.cc).sub.2,
--NR.sub.bbP(.dbd.O)(NR.sup.bb).sub.2, --P(R.sup.cc).sub.2,
--P(R.sup.cc).sub.3, --OP(R.sup.cc).sub.2, --OP(R.sup.cc).sub.3,
--B(R.sup.aa).sub.2, --B(OR.sup.cc).sub.2, --BR.sup.aa(OR.sup.cc),
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl,
wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,
aryl, and heteroaryl is independently substituted with 0, 1, 2, 3,
4, or 5 R.sup.dd groups;
[0119] each instance of R.sup.aa is, independently, selected from
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two
R.sup.aa groups are joined to form a 3-14 membered heterocyclyl or
5-14 membered heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0120] each instance of R.sup.bb is, independently, selected from
hydrogen, --OH, --OR.sup.aa, --N(R.sup.cc).sub.2, --CN,
--C(.dbd.O)R.sup.aa, --C(.dbd.O)N(R.sup.cc).sub.2,
--CO.sub.2R.sup.aa, --SO.sub.2R.sup.aa,
--C(.dbd.NR.sub.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O).sub.2N(R.sup.cc).sub.2, --P(.dbd.O)(NR.sup.cc).sub.2,
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two
R.sup.bb groups are joined to form a 3-14 membered heterocyclyl or
5-14 membered heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0121] each instance of R.sup.cc is, independently, selected from
hydrogen, C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10
alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14 membered heteroaryl, or two
R.sup.cc groups are joined to form a 3-14 membered heterocyclyl or
5-14 membered heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.dd
groups;
[0122] each instance of R.sup.dd is, independently, selected from
halogen, --CN, --NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H,
--OH, --OR.sup.ee, --ON(R.sup.ff).sub.2, --N(R.sup.ff).sub.2,
--N(R.sup.ff).sub.3.sup.+X.sup.-, --N(OR.sup.ee)R.sup.ff, --SH,
--SR.sup.ee, --SSR.sup.ee, --C(.dbd.O)R.sup.ee, --CO.sub.2H,
--CO.sub.2R.sup.ee, --OC(.dbd.O)R.sup.ee, --OCO.sub.2R.sup.ee,
--C(.dbd.O)N(R.sup.ff).sub.2, --OC(.dbd.O)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.O)R.sup.ee, --NR.sup.ffCO.sub.2R.sup.ee,
--NR.sup.ffC(.dbd.O)N(R.sup.ff).sub.2,
--C(.dbd.NR.sup.ff)OR.sup.ee, --OC(.dbd.NR.sup.ff)R.sup.ee,
--OC(.dbd.NR.sup.ff)OR.sup.ee,
--C(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--OC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffC(.dbd.NR.sup.ff)N(R.sup.ff).sub.2,
--NR.sup.ffSO.sub.2R.sup.ee, --SO.sub.2N(R.sup.ff).sub.2,
--SO.sub.2R.sup.ee, --SO.sub.2OR.sup.ee, --OSO.sub.2R.sup.ee,
--S(.dbd.O)R.sup.ee, --Si(R.sup.ee).sub.3, --OSi(R.sup.ee).sub.3,
--C(.dbd.S)N(R.sup.ff).sub.2, --C(.dbd.O)SR.sup.ee,
--C(.dbd.S)SR.sup.ee, --SC(.dbd.S)SR.sup.ee,
--P(.dbd.O).sub.2R.sup.ee, --P(.dbd.O)(R.sup.ee).sub.2,
--OP(.dbd.O)(R.sup.ee).sub.2, --OP(.dbd.O)(OR.sup.ee).sub.2,
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, 3-10 membered
heterocyclyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, wherein
each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5
R.sup.gg groups;
[0123] each instance of R.sup.ee is, independently, selected from
C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl, 3-10
membered heterocyclyl, and 3-10 membered heteroaryl, wherein each
alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and
heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5
R.sup.gg groups;
[0124] each instance of R.sup.ff is, independently, selected from
hydrogen, C.sub.1-6 alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 carbocyclyl, 3-10 membered
heterocyclyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, or two
R.sup.ff groups are joined to form a 3-14 membered heterocyclyl or
5-14 membered heteroaryl ring, wherein each alkyl, alkenyl,
alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is
independently substituted with 0, 1, 2, 3, 4, or 5 R.sup.gg groups;
and
[0125] each instance of R.sup.gg is, independently, halogen, --CN,
--NO.sub.2, --N.sub.3, --SO.sub.2H, --SO.sub.3H, --OH, --OC.sub.1-6
alkyl, --ON(C.sub.1-6 alkyl).sub.2, --N(C.sub.1-6 alkyl).sub.2,
--N(C.sub.1-6 alkyl).sub.3.sup.+X.sup.-, --NH(C.sub.1-6
alkyl).sub.2.sup.+X.sup.-, --NH.sub.2(C.sub.1-6
alkyl).sup.+X.sup.-, --NH.sub.3.sup.+X.sup.-, --N(OC.sub.1-6
alkyl)(C.sub.1-6 alkyl), --N(OH)(C.sub.1-6 alkyl), --NH(OH), --SH,
--SC.sub.1-6 alkyl, --SS(C.sub.1-6 alkyl), --C(.dbd.O)(C.sub.1-6
alkyl), --CO.sub.2H, --CO.sub.2(C.sub.1-6 alkyl),
--OC(.dbd.O)(C.sub.1-6 alkyl), --OCO.sub.2(C.sub.1-6 alkyl),
--C(.dbd.O)NH.sub.2, --C(.dbd.O)N(C.sub.1-6 alkyl).sub.2,
--OC(.dbd.O)NH(C.sub.1-6 alkyl), --NHC(.dbd.O)(C.sub.1-6 alkyl),
--N(C.sub.1-6 alkyl)C(.dbd.O)(C.sub.1-6 alkyl),
--NHCO.sub.2(C.sub.1-6 alkyl), --NHC(.dbd.O)N(C.sub.1-6
alkyl).sub.2, --NHC(.dbd.O)NH(C.sub.1-6 alkyl),
--NHC(.dbd.O)NH.sub.2, --C(.dbd.NH)O(C.sub.1-6 alkyl),
--OC(.dbd.NH)(C.sub.1-6 alkyl), --OC(.dbd.NH)OC.sub.1-6 alkyl,
--C(.dbd.NH)N(C.sub.1-6 alkyl).sub.2, --C(.dbd.NH)NH(C.sub.1-6
alkyl), --C(.dbd.NH)NH.sub.2, --OC(.dbd.NH)N(C.sub.1-6
alkyl).sub.2, --OC(NH)NH(C.sub.1-6 alkyl), --OC(NH)NH.sub.2,
--NHC(NH)N(C.sub.1-6 alkyl).sub.2, --NHC(.dbd.NH)NH.sub.2,
--NHSO.sub.2(C.sub.1-6 alkyl), --SO.sub.2N(C.sub.1-6 alkyl).sub.2,
--SO.sub.2NH(C.sub.1-6 alkyl), --SO.sub.2NH.sub.2,
--SO.sub.2C.sub.1-6 alkyl, --SO.sub.2OC.sub.1-6 alkyl,
--OSO.sub.2C.sub.1-6 alkyl, --SOC.sub.1-6 alkyl, --Si(C.sub.1-6
alkyl).sub.3, --OSi(C.sub.1-6 alkyl).sub.3-C(.dbd.S)N(C.sub.1-6
alkyl).sub.2, C(.dbd.S)NH(C.sub.1-6 alkyl), C(.dbd.S)NH.sub.2,
--C(.dbd.O)S(C.sub.1-6 alkyl), --C(.dbd.S)SC.sub.1-6 alkyl,
--SC(.dbd.S)SC.sub.1-6 alkyl, --P(.dbd.O).sub.2(C.sub.1-6 alkyl),
--P(.dbd.O)(C.sub.1-6 alkyl).sub.2, --OP(.dbd.O)(C.sub.1-6
alkyl).sub.2, --OP(.dbd.O)(OC.sub.1-6 alkyl).sub.2, C.sub.1-6
alkyl, C.sub.1-6 perhaloalkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-10 carbocyclyl, C.sub.6-10 aryl, 3-10 membered
heterocyclyl, 5-10 membered heteroaryl; wherein X.sup.- is a
counterion.
[0126] A "counterion" or "anionic counterion" is a negatively
charged group associated with a cationic quaternary amino group in
order to maintain electronic neutrality. Exemplary counterions
include halide ions (e.g., F.sup.-, Cl.sup.-, Br.sup.-, I.sup.-),
NO.sub.3.sup.-, ClO.sub.4.sup.-, OH.sup.-, H.sub.2PO.sub.4.sup.-,
HSO.sub.4.sup.-, sulfonate ions (e.g., methansulfonate,
trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate,
10-camphor sulfonate, naphthalene-2-sulfonate,
naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic
acid-2-sulfonate, and the like), and carboxylate ions (e.g.,
acetate, ethanoate, propanoate, benzoate, glycerate, lactate,
tartrate, glycolate, and the like).
[0127] Nitrogen atoms can be substituted or unsubstituted as
valency permits, and include primary, secondary, tertiary, and
quarternary nitrogen atoms. Exemplary nitrogen atom substitutents
include, but are not limited to, hydrogen, --OH, --OR.sup.aa,
--N(R.sup.cc).sub.2, --CN, --C(.dbd.O)R.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --CO.sub.2R.sup.aa,
--SO.sub.2R.sup.aa, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.cc)OR.sup.aa, --C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2,
--SO.sub.2N(R.sup.cc).sub.2, --SO.sub.2R.sup.cc,
--SO.sub.2OR.sup.cc, --SOR.sup.aa, --C(.dbd.S)N(R.sup.cc).sub.2,
--C(.dbd.O)SR.sup.cc, --C(.dbd.S)SR.sup.cc,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O).sub.2N(R.sup.cc).sub.2, --P(.dbd.O)(NR.sup.cc).sub.2,
C.sub.1-10 alkyl, C.sub.1-10 perhaloalkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14 membered
heterocyclyl, C.sub.6-14 aryl, and 5-14-membered heteroaryl, or two
R.sup.cc groups attached to a nitrogen atom are joined to form a
3-14-membered heterocyclyl or 5-14-membered heteroaryl ring,
wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,
aryl, and heteroaryl is independently substituted with 0, 1, 2, 3,
4, or 5 R.sup.dd groups, and wherein R.sup.aa, R.sup.bb, R.sup.cc
and R.sup.dd are as defined above.
[0128] In certain embodiments, the substituent present on a
nitrogen atom is an amino protecting group (also referred to herein
as a nitrogen protecting group). Amino protecting groups include,
but are not limited to, --OH, --OR.sup.aa, --N(R.sup.cc).sub.2,
--C(.dbd.O)R.sup.aa, --C(.dbd.O)OR.sup.aa,
--C(.dbd.O)N(R.sup.cc).sub.2, --S(.dbd.O).sub.2R.sup.aa,
--C(.dbd.NR.sup.cc)R.sup.aa, --C(.dbd.NR.sup.cc)OR.sup.aa,
--C(.dbd.NR.sup.cc)N(R.sup.cc).sub.2, --SO.sub.2N(R.sup.cc).sub.2,
--SO.sub.2R.sup.cc, --SO.sub.2OR.sup.cc, --SOR.sup.aa,
--C(.dbd.S)N(R.sup.cc).sub.2, --C(.dbd.O)SR.sup.cc,
--C(.dbd.S)SR.sup.cc, C.sub.1-10 alkyl, C.sub.2-10 alkenyl,
C.sub.2-10 alkynyl, C.sub.3-10 carbocyclyl, 3-14-membered
heterocyclyl, C.sub.6-14 aryl, and 5-14-membered heteroaryl groups,
wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,
aryl, and heteroaryl is independently substituted with 0, 1, 2, 3,
4, or 5 R.sup.dd groups, and wherein R.sup.aa, R.sup.bb, R.sup.cc
and R.sup.dd are as defined herein. Amino protecting groups are
well known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0129] Exemplary amino protecting groups include, but are not
limited to amide groups (e.g., --C(.dbd.O)R.sup.aa), which include,
but are not limited to, formamide and acetamide; carbamate groups
(e.g., --C(.dbd.O)OR.sup.aa), which include, but are not limited
to, 9-fluorenylmethyl carbamate (Fmoc), t-butyl carbamate (BOC),
and benzyl carbamate (Cbz); sulfonamide groups (e.g.,
--S(.dbd.O).sub.2R.sup.aa), which include, but are not limited to,
p-toluenesulfonamide (Ts), methanesulfonamide (Ms), and
N-[2-(trimethylsilyl)ethoxy]methylamine (SEM).
[0130] In certain embodiments, the substituent present on an oxygen
atom is an oxygen protecting group (also referred to as a hydroxyl
protecting group). Oxygen protecting groups include, but are not
limited to, --R.sup.aa, --N(R.sup.bb).sub.2, --C(.dbd.O)SR.sup.aa,
--C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
and --P(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and
R.sup.cc are as defined herein. Oxygen protecting groups are well
known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0131] Exemplary oxygen protecting groups include, but are not
limited to, methyl, methoxylmethyl (MOM), 2-methoxyethoxymethyl
(MEM), benzyl (Bn), triisopropylsilyl (TIPS), t-butyldimethylsilyl
(TBDMS), t-butylmethoxyphenylsilyl (TBMPS), methanesulfonate
(mesylate), and tosylate (Ts).
[0132] In certain embodiments, the substituent present on an sulfur
atom is an sulfur protecting group (also referred to as a thiol
protecting group). Sulfur protecting groups include, but are not
limited to, --R.sup.aa, --N(R.sup.bb).sub.2, --C(.dbd.O)SR.sup.aa,
--C(.dbd.O)R.sup.aa, --CO.sub.2R.sup.aa,
--C(.dbd.O)N(R.sup.bb).sub.2, --C(.dbd.NR.sup.bb)R.sup.aa,
--C(.dbd.NR.sup.bb)OR.sup.aa, --C(.dbd.NR.sup.bb)N(R.sup.bb).sub.2,
--S(.dbd.O)R.sup.aa, --SO.sub.2R.sup.aa, --Si(R.sup.aa).sub.3,
--P(R.sup.cc).sub.2, --P(R.sup.cc).sub.3,
--P(.dbd.O).sub.2R.sup.aa, --P(.dbd.O)(R.sup.aa).sub.2,
--P(.dbd.O)(OR.sup.cc).sub.2, --P(.dbd.O).sub.2N(R.sup.bb).sub.2,
and --P(.dbd.O)(NR.sup.bb).sub.2, wherein R.sup.aa, R.sup.bb, and
R.sup.cc are as defined herein. Sulfur protecting groups are well
known in the art and include those described in detail in
Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.
Wuts, 3.sup.rd edition, John Wiley & Sons, 1999, incorporated
herein by reference.
[0133] These and other exemplary substituents are described in more
detail in the Detailed Description, Examples, and Claims. The
invention is not intended to be limited in any manner by the above
exemplary listing of substituents.
Other Definitions
[0134] As used herein, the term "modulation" refers to the
inhibition or potentiation of GABA receptor function. A "modulator"
(e.g., a modulator compound) may be, for example, an agonist,
partial agonist, antagonist, or partial antagonist of the GABA
receptor.
[0135] "Pharmaceutically acceptable" means approved or approvable
by a regulatory agency of the Federal or a state government or the
corresponding agency in countries other than the United States, or
that is listed in the U.S. Pharmacopoeia or other generally
recognized pharmacopoeia for use in animals, and more particularly,
in humans.
[0136] "Pharmaceutically acceptable salt" refers to a salt of a
compound of the invention that is pharmaceutically acceptable and
that possesses the desired pharmacological activity of the parent
compound. In particular, such salts are non-toxic may be inorganic
or organic acid addition salts and base addition salts.
Specifically, such salts include: (1) acid addition salts, formed
with inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, phosphoric acid, and the like; or
formed with organic acids such as acetic acid, propionic acid,
hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic
acid, lactic acid, malonic acid, succinic acid, malic acid, maleic
acid, fumaric acid, tartaric acid, citric acid, benzoic acid,
3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic
acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid,
4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
4-toluenesulfonic acid, camphorsulfonic acid,
4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic
acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary
butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic
acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic
acid, and the like; or (2) salts formed when an acidic proton
present in the parent compound either is replaced by a metal ion,
e.g., an alkali metal ion, an alkaline earth ion, or an aluminum
ion; or coordinates with an organic base such as ethanolamine,
diethanolamine, triethanolamine, N-methylglucamine and the like.
Salts further include, by way of example only, sodium, potassium,
calcium, magnesium, ammonium, tetraalkylammonium, and the like; and
when the compound contains a basic functionality, salts of
non-toxic organic or inorganic acids, such as hydrochloride,
hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the
like. The term "pharmaceutically acceptable cation" refers to an
acceptable cationic counter-ion of an acidic functional group. Such
cations are exemplified by sodium, potassium, calcium, magnesium,
ammonium, tetraalkylammonium cations, and the like. See, e.g.,
Berge, et al., J. Pharm. Sci. (1977) 66(1): 1-79.
[0137] "Solvate" refers to forms of the compound that are
associated with a solvent or water (also referred to as "hydrate"),
usually by a solvolysis reaction. This physical association
includes hydrogen bonding. Conventional solvents include water,
ethanol, acetic acid, and the like. The compounds of the invention
may be prepared e.g. in crystalline form and may be solvated or
hydrated. Suitable solvates include pharmaceutically acceptable
solvates, such as hydrates, and further include both stoichiometric
solvates and non-stoichiometric solvates. In certain instances the
solvate will be capable of isolation, for example when one or more
solvent molecules are incorporated in the crystal lattice of the
crystalline solid. "Solvate" encompasses both solution-phase and
isolable solvates. Representative solvates include hydrates,
ethanolates and methanolates.
[0138] As used herein, the term "isotopic variant" refers to a
compound that contains unnatural proportions of isotopes at one or
more of the atoms that constitute such compound. For example, an
"isotopic variant" of a compound can contain one or more
non-radioactive isotopes, such as for example, deuterium (.sup.2H
or D), carbon-13 (.sup.13C), nitrogen-15 (.sup.15N), or the like.
It will be understood that, in a compound where such isotopic
substitution is made, the following atoms, where present, may vary,
so that for example, any hydrogen may be .sup.2H/D, any carbon may
be .sup.13C, or any nitrogen may be .sup.15N, and that the presence
and placement of such atoms may be determined within the skill of
the art. Likewise, the invention may include the preparation of
isotopic variants with radioisotopes, in the instance for example,
where the resulting compounds may be used for drug and/or substrate
tissue distribution studies. The radioactive isotopes tritium,
i.e., .sup.3H, and carbon-14, i.e., .sup.14C, are particularly
useful for this purpose in view of their ease of incorporation and
ready means of detection. Further, compounds may be prepared that
are substituted with positron emitting isotopes, such as .sup.11C,
.sup.18F, .sup.15O, and .sup.13N, and would be useful in Positron
Emission Topography (PET) studies for examining substrate receptor
occupancy. All isotopic variants of the compounds provided herein,
radioactive or not, are intended to be encompassed within the scope
of the invention.
[0139] "Stereoisomers": It is also to be understood that compounds
that have the same molecular formula but differ in the nature or
sequence of bonding of their atoms or the arrangement of their
atoms in space are termed "isomers." Isomers that differ in the
arrangement of their atoms in space are termed "stereoisomers."
Stereoisomers that are not mirror images of one another are termed
"diastereomers" and those that are non-superimposable mirror images
of each other are termed "enantiomers." When a compound has an
asymmetric center, for example, it is bonded to four different
groups, a pair of enantiomers is possible. An enantiomer can be
characterized by the absolute configuration of its asymmetric
center and is described by the R- and S-sequencing rules of Cahn
and Prelog, or by the manner in which the molecule rotates the
plane of polarized light and designated as dextrorotatory or
levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral
compound can exist as either individual enantiomer or as a mixture
thereof. A mixture containing equal proportions of the enantiomers
is called a "racemic mixture".
[0140] "Tautomers" refer to compounds that are interchangeable
forms of a particular compound structure, and that vary in the
displacement of hydrogen atoms and electrons. Thus, two structures
may be in equilibrium through the movement of .pi. electrons and an
atom (usually H). For example, enols and ketones are tautomers
because they are rapidly interconverted by treatment with either
acid or base. Another example of tautomerism is the aci- and
nitro-forms of phenylnitromethane, that are likewise formed by
treatment with acid or base. Tautomeric forms may be relevant to
the attainment of the optimal chemical reactivity and biological
activity of a compound of interest.
[0141] A "subject" to which administration is contemplated
includes, but is not limited to, humans (i.e., a male or female of
any age group, e.g., a pediatric subject (e.g, infant, child,
adolescent) or adult subject (e.g., young adult, middle-aged adult
or senior adult)) and/or a non-human animal, e.g., a mammal such as
primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs,
horses, sheep, goats, rodents, cats, and/or dogs. In certain
embodiments, the subject is a human. In certain embodiments, the
subject is a non-human animal. The terms "human," "patient," and
"subject" are used interchangeably herein.
[0142] Disease, disorder, and condition are used interchangeably
herein.
[0143] As used herein, and unless otherwise specified, the terms
"treat," "treating" and "treatment" contemplate an action that
occurs while a subject is suffering from the specified disease,
disorder or condition, which reduces the severity of the disease,
disorder or condition, or retards or slows the progression of the
disease, disorder or condition ("therapeutic treatment"), and also
contemplates an action that occurs before a subject begins to
suffer from the specified disease, disorder or condition
("prophylactic treatment").
[0144] In general, the "effective amount" of a compound refers to
an amount sufficient to elicit the desired biological response,
e.g., to treat a CNS-related disorder, is sufficient to induce
anesthesia or sedation. As will be appreciated by those of ordinary
skill in this art, the effective amount of a compound of the
invention may vary depending on such factors as the desired
biological endpoint, the pharmacokinetics of the compound, the
disease being treated, the mode of administration, and the age,
weight, health, and condition of the subject. An effective amount
encompasses therapeutic and prophylactic treatment.
[0145] As used herein, and unless otherwise specified, a
"therapeutically effective amount" of a compound is an amount
sufficient to provide a therapeutic benefit in the treatment of a
disease, disorder or condition, or to delay or minimize one or more
symptoms associated with the disease, disorder or condition. A
therapeutically effective amount of a compound means an amount of
therapeutic agent, alone or in combination with other therapies,
which provides a therapeutic benefit in the treatment of the
disease, disorder or condition. The term "therapeutically effective
amount" can encompass an amount that improves overall therapy,
reduces or avoids symptoms or causes of disease or condition, or
enhances the therapeutic efficacy of another therapeutic agent.
[0146] As used herein, and unless otherwise specified, a
"prophylactically effective amount" of a compound is an amount
sufficient to prevent a disease, disorder or condition, or one or
more symptoms associated with the disease, disorder or condition,
or prevent its recurrence. A prophylactically effective amount of a
compound means an amount of a therapeutic agent, alone or in
combination with other agents, which provides a prophylactic
benefit in the prevention of the disease, disorder or condition.
The term "prophylactically effective amount" can encompass an
amount that improves overall prophylaxis or enhances the
prophylactic efficacy of another prophylactic agent.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
[0147] As generally described herein, the present invention
provides C21-substituted neuroactive steroids designed, for
example, to act as GABA modulators. In certain embodiments, such
compounds are envisioned to be useful as therapeutic agents for the
inducement of anesthesia and/or sedation in a subject. In certain
embodiments, such compounds are envisioned to be useful as
therapeutic agents for treating a CNS-related disorder.
Compounds
[0148] In one aspect, provided is a compound of Formula (I):
##STR00026##
or a pharmaceutically acceptable salt thereof, wherein: A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
and represents a single or double bond, wherein when one of is a
double bond, the other is a single bond; and when one of the is a
double bond, R.sup.3 is absent.
[0149] In some embodiments, R.sup.1 is substituted or unsubstituted
C.sub.1-6 alkyl (e.g., haloalkyl). In some embodiments, R.sup.1 is
methyl or CF.sub.3.
[0150] In some embodiments, R.sup.2a is substituted or
unsubstituted C.sub.1-6 alkyl. In some embodiments, R.sup.2a is
methyl. In some embodiments, R.sup.2b is hydrogen. In some
embodiments, R.sup.2b is substituted or unsubstituted C.sub.1-6
alkyl. In some embodiments, R.sup.2a is methyl. In some
embodiments, R.sup.2a is methyl and R.sup.2b is hydrogen.
[0151] In some embodiments, R.sup.3 is absent. In some embodiments,
R.sup.3 is hydrogen.
[0152] In some embodiments, represents a single bond. In some
embodiments, one of represents a double bond and the other
represents a single bond.
[0153] In some embodiments, the compound of Formula (I) is a
compound of Formula (II) or Formula (III):
##STR00027##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, and R.sup.2b are defined as for Formula (I).
[0154] In some embodiments, the compound of Formula (II) is a
compound of Formula (II-a) or Formula (II-b):
##STR00028##
or a pharmaceutically acceptable salt thereof, wherein A and
R.sup.1 are defined as for Formula (I).
[0155] In some embodiments, the compound of Formula (III) is a
compound of Formula (III-a) or Formula (III-b):
##STR00029##
or a pharmaceutically acceptable salt thereof, wherein A and
R.sup.1 are defined as for Formula (I).
[0156] In some embodiments, A is heterocyclyl or heteroaryl (e.g.,
nitrogen-containing heterocyclyl or a nitrogen-containing
heteroaryl). In some embodiments, A is monocyclic or bicyclic. In
some embodiments, A is substituted with at least one R.sup.A,
wherein R.sup.A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, C.sub.1-6 haloalkyl, halogen, cyano,
--OR.sup.A6, --C(.dbd.O)OR.sup.A6, --SR.sup.B6,
--S(.dbd.O)R.sup.B6, or S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6
is hydrogen or C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, or C.sub.1-6 haloalkyl, and R.sup.B6
is C.sub.1-6 alkyl or C.sub.3-6 carbocylyl. In some embodiments,
R.sup.A is C.sub.1-6 alkyl, halogen, or cyano. In some embodiments,
A is substituted with 1-3 instances of R.sup.A.
[0157] In another aspect, provided is a compound of the Formula
(IV):
##STR00030##
or a pharmaceutically acceptable salt thereof wherein A is aryl,
heterocyclyl or heteroaryl; R.sup.1 is C.sub.1-6 alkyl; R.sup.2a is
C.sub.1-6 alkyl; R.sup.2b is hydrogen or C.sub.1-6 alkyl; or
R.sup.2a and R.sup.2b are joined to form an oxo (.dbd.O) group; or
R.sup.2a and R.sup.2b together with the carbon atom to which they
are attached form a ring (e.g., a 3-6-membered ring (e.g.,
carbocycyl or heterocyclyl ring)); R.sup.3 is absent or hydrogen;
R.sup.A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 carbocylyl, C.sub.1-6 haloalkyl, halogen, cyano,
--OR.sup.A6, --C(.dbd.O)OR.sup.A6, --SR.sup.B6,
--S(.dbd.O)R.sup.B6, or S(.dbd.O).sub.2R.sup.B6, wherein R.sup.A6
is hydrogen or C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 carbocylyl, or C.sub.1-6 haloalkyl, and R.sup.B6
is C.sub.1-6 alkyl or C.sub.3-6 carbocylyl; n is 0, 1, 2 or 3; and
represents a single or double bond, wherein when one of is a double
bond, the other is a single bond; and when one of the is a double
bond, R.sup.3 is absent.
[0158] In some embodiments, R.sup.1 is substituted or unsubstituted
C.sub.1-6 alkyl (e.g., haloalkyl). In some embodiments, R.sup.1 is
methyl or CF.sub.3.
[0159] In some embodiments, R.sup.2a is substituted or
unsubstituted C.sub.1-6 alkyl. In some embodiments, R.sup.2a is
methyl. In some embodiments, R.sup.2b is hydrogen. In some
embodiments, R.sup.2b is substituted or unsubstituted C.sub.1-6
alkyl. In some embodiments, R.sup.2a is methyl. In some
embodiments, R.sup.2a is methyl and R.sup.2b is hydrogen.
[0160] In some embodiments, R.sup.3 is absent. In some embodiments,
R.sup.3 is hydrogen.
[0161] In some embodiments, represents a single bond. In some
embodiments, one of represents a double bond and the other
represents a single bond.
[0162] In some embodiments, the compound of Formula (IV) is a
compound of Formula (V) or Formula (VI):
##STR00031##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for Formula
(IV).
[0163] In some embodiments, the compound of Formula (V) is a
compound of Formula (V-a) or Formula (V-b):
##STR00032##
or a pharmaceutically acceptable salt thereof, wherein wherein A,
R.sup.1, R.sup.2a, R.sup.2b, R.sup.A, and n are defined as for
Formula (IV).
[0164] In some embodiments, the compound of Formula (VI) is a
compound of Formula (VI-a) or Formula (VI-b):
##STR00033##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
are defined as for Formula (I).
[0165] In some embodiments, A is selected from:
##STR00034##
[0166] In some embodiments, A is:
##STR00035##
[0167] In some embodiments, the compound is selected from:
##STR00036## ##STR00037## ##STR00038## ##STR00039##
or a pharmaceutically acceptable salt thereof.
[0168] In one aspect, provided is a method for treating disorders
related to GABA function in a subject in need thereof, the method
comprising administering to the subject a therapeutically effective
amount of a compound, a pharmaceutically acceptable salt thereof,
or pharmaceutical composition of one of a compound as described
herein, e.g., a compound of the Formula (I), Formula (II) (e.g.,
(II-a), (II-b)), Formula (III) (e.g., (III-a), (III-b)), Formula
(IV), Formula (V) (e.g., (V-a), (V-b)), or Formula (VI) (e.g.,
(VI-a) or (VI-b)).
[0169] In one aspect, provided is a method for treating a
CNS-related disorder in a subject in need thereof, comprising
administering to the subject an effective amount of a compound as
described herein, e.g., a compound of the Formula (I), Formula (II)
(e.g., (II-a), (II-b)), Formula (III) (e.g., (III-a), (III-b)),
Formula (IV), Formula (V) (e.g., (V-a), (V-b)), or Formula (VI)
(e.g., (VI-a) or (VI-b)), or a pharmaceutically acceptable salt
thereof. In some embodiments, the CNS-related disorder is a sleep
disorder, a mood disorder such as depression, a schizophrenia
spectrum disorder, a convulsive disorder, a disorder of memory
and/or cognition, a movement disorder, a personality disorder,
autism spectrum disorder, pain, traumatic brain injury, a vascular
disease, a substance abuse disorder and/or withdrawal syndrome, or
tinnitus. In some embodiments, the subject is a subject with Rett
syndrome, Fragile X syndrome, or Angelman syndrome.
[0170] In one aspect, provided is a kit comprising a solid
composition comprising a compound as described herein, e.g., a
compound of the Formula (I), Formula (II) (e.g., (II-a), (II-b)),
Formula (III) (e.g., (III-a), (III-b)), Formula (IV), Formula (V)
(e.g., (V-a), (V-b)), or Formula (VI) (e.g., (VI-a) or (VI-b)), and
a sterile diluent.
Pharmaceutical Compositions
[0171] In one aspect, the invention provides a pharmaceutical
composition comprising a compound of the present invention (also
referred to as the "active ingredient") and a pharmaceutically
acceptable excipient. In certain embodiments, the pharmaceutical
composition comprises an effective amount of the active ingredient.
In certain embodiments, the pharmaceutical composition comprises a
therapeutically effective amount of the active ingredient. In
certain embodiments, the pharmaceutical composition comprises a
prophylactically effective amount of the active ingredient.
[0172] The pharmaceutical compositions provided herein can be
administered by a variety of routes including, but not limited to,
oral (enteral) administration, parenteral (by injection)
administration, rectal administration, transdermal administration,
intradermal administration, intrathecal administration,
subcutaneous (SC) administration, intravenous (IV) administration,
intramuscular (IM) administration, and intranasal
administration.
[0173] Generally, the compounds provided herein are administered in
an effective amount. The amount of the compound actually
administered will typically be determined by a physician, in the
light of the relevant circumstances, including the condition to be
treated, the chosen route of administration, the actual compound
administered, the age, weight, and response of the individual
patient, the severity of the patient's symptoms, and the like.
[0174] When used to prevent the onset of a CNS-disorder, the
compounds provided herein will be administered to a subject at risk
for developing the condition, typically on the advice and under the
supervision of a physician, at the dosage levels described above.
Subjects at risk for developing a particular condition generally
include those that have a family history of the condition, or those
who have been identified by genetic testing or screening to be
particularly susceptible to developing the condition.
[0175] The pharmaceutical compositions provided herein can also be
administered chronically ("chronic administration"). Chronic
administration refers to administration of a compound or
pharmaceutical composition thereof over an extended period of time,
e.g., for example, over 3 months, 6 months, 1 year, 2 years, 3
years, 5 years, etc, or may be continued indefinitely, for example,
for the rest of the subject's life. In certain embodiments, the
chronic administration is intended to provide a constant level of
the compound in the blood, e.g., within the therapeutic window over
the extended period of time.
[0176] The pharmaceutical compostions of the present invention may
be further delivered using a variety of dosing methods. For
example, in certain embodiments, the pharmaceutical composition may
be given as a bolus, e.g., in order to raise the concentration of
the compound in the blood to an effective level. The placement of
the bolus dose depends on the systemic levels of the active
ingredient desired throughout the body, e.g., an intramuscular or
subcutaneous bolus dose allows a slow release of the active
ingredient, while a bolus delivered directly to the veins (e.g.,
through an IV drip) allows a much faster delivery which quickly
raises the concentration of the active ingredient in the blood to
an effective level. In other embodiments, the pharmaceutical
composition may be administered as a continuous infusion, e.g., by
IV drip, to provide maintenance of a steady-state concentration of
the active ingredient in the subject's body. Furthermore, in still
yet other embodiments, the pharmaceutical composition may be
administered as first as a bolus dose, followed by continuous
infusion.
[0177] The compositions for oral administration can take the form
of bulk liquid solutions or suspensions, or bulk powders. More
commonly, however, the compositions are presented in unit dosage
forms to facilitate accurate dosing. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for
human subjects and other mammals, each unit containing a
predetermined quantity of active material calculated to produce the
desired therapeutic effect, in association with a suitable
pharmaceutical excipient. Typical unit dosage forms include
prefilled, premeasured ampules or syringes of the liquid
compositions or pills, tablets, capsules or the like in the case of
solid compositions. In such compositions, the compound is usually a
minor component (from about 0.1 to about 50% by weight or
preferably from about 1 to about 40% by weight) with the remainder
being various vehicles or excipients and processing aids helpful
for forming the desired dosing form.
[0178] With oral dosing, one to five and especially two to four and
typically three oral doses per day are representative regimens.
Using these dosing patterns, each dose provides from about 0.01 to
about 20 mg/kg of the compound provided herein, with preferred
doses each providing from about 0.1 to about 10 mg/kg, and
especially about 1 to about 5 mg/kg.
[0179] Transdermal doses are generally selected to provide similar
or lower blood levels than are achieved using injection doses,
generally in an amount ranging from about 0.01 to about 20% by
weight, preferably from about 0.1 to about 20% by weight,
preferably from about 0.1 to about 10% by weight, and more
preferably from about 0.5 to about 15% by weight.
[0180] Injection dose levels range from about 0.1 mg/kg/hour to at
least 20 mg/kg/hour, all for from about 1 to about 120 hours and
especially 24 to 96 hours. A preloading bolus of from about 0.1
mg/kg to about 10 mg/kg or more may also be administered to achieve
adequate steady state levels. The maximum total dose is not
expected to exceed about 5 g/day for a 40 to 80 kg human
patient.
[0181] Liquid forms suitable for oral administration may include a
suitable aqueous or nonaqueous vehicle with buffers, suspending and
dispensing agents, colorants, flavors and the like. Solid forms may
include, for example, any of the following ingredients, or
compounds of a similar nature: a binder such as microcrystalline
cellulose, gum tragacanth or gelatin; an excipient such as starch
or lactose, a disintegrating agent such as alginic acid, Primogel,
or corn starch; a lubricant such as magnesium stearate; a glidant
such as colloidal silicon dioxide; a sweetening agent such as
sucrose or saccharin; or a flavoring agent such as peppermint,
methyl salicylate, or orange flavoring.
[0182] Injectable compositions are typically based upon injectable
sterile saline or phosphate-buffered saline or other injectable
excipients known in the art. As before, the active compound in such
compositions is typically a minor component, often being from about
0.05 to 10% by weight with the remainder being the injectable
excipient and the like.
[0183] Transdermal compositions are typically formulated as a
topical ointment or cream containing the active ingredient(s). When
formulated as a ointment, the active ingredients will typically be
combined with either a paraffinic or a water-miscible ointment
base. Alternatively, the active ingredients may be formulated in a
cream with, for example an oil-in-water cream base. Such
transdermal formulations are well-known in the art and generally
include additional ingredients to enhance the dermal penetration of
stability of the active ingredients or Formulation. All such known
transdermal formulations and ingredients are included within the
scope provided herein.
[0184] The compounds provided herein can also be administered by a
transdermal device. Accordingly, transdermal administration can be
accomplished using a patch either of the reservoir or porous
membrane type, or of a solid matrix variety.
[0185] The above-described components for orally administrable,
injectable or topically administrable compositions are merely
representative. Other materials as well as processing techniques
and the like are set forth in Part 8 of Remington's Pharmaceutical
Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pa.,
which is incorporated herein by reference.
[0186] The compounds of the present invention can also be
administered in sustained release forms or from sustained release
drug delivery systems. A description of representative sustained
release materials can be found in Remington's Pharmaceutical
Sciences.
[0187] The present invention also relates to the pharmaceutically
acceptable acid addition salt of a compound of the present
invention. The acid which may be used to prepare the
pharmaceutically acceptable salt is that which forms a non-toxic
acid addition salt, i.e., a salt containing pharmacologically
acceptable anions such as the hydrochloride, hydroiodide,
hydrobromide, nitrate, sulfate, bisulfate, phosphate, acetate,
lactate, citrate, tartrate, succinate, maleate, fumarate, benzoate,
para-toluenesulfonate, and the like.
[0188] In another aspect, the invention provides a pharmaceutical
composition comprising a compound of the present invention and a
pharmaceutically acceptable excipient, e.g., a composition suitable
for injection, such as for intravenous (IV) administration.
[0189] Pharmaceutically acceptable excipients include any and all
diluents or other liquid vehicles, dispersion or suspension aids,
surface active agents, isotonic agents, preservatives, lubricants
and the like, as suited to the particular dosage form desired,
e.g., injection. General considerations in the formulation and/or
manufacture of pharmaceutical compositions agents can be found, for
example, in Remington's Pharmaceutical Sciences, Sixteenth Edition,
E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and
Remington: The Science and Practice of Pharmacy, 21.sup.st Edition
(Lippincott Williams & Wilkins, 2005).
[0190] For example, injectable preparations, such as sterile
injectable aqueous suspensions, can be formulated according to the
known art using suitable dispersing or wetting agents and
suspending agents. Exemplary excipients that can be employed
include, but are not limited to, water, sterile saline or
phosphate-buffered saline, or Ringer's solution.
[0191] In certain embodiments, the pharmaceutical composition
further comprises a cyclodextrin derivative. The most common
cyclodextrins are .alpha.-, .beta.- and .gamma.-cyclodextrins
consisting of 6, 7 and 8 .alpha.-1,4-linked glucose units,
respectively, optionally comprising one or more substituents on the
linked sugar moieties, which include, but are not limited to,
substituted or unsubstituted methylated, hydroxyalkylated,
acylated, and sulfoalkylether substitution. In certain embodiments,
the cyclodextrin is a sulfoalkyl ether .beta.-cyclodextrin, e.g.,
for example, sulfobutyl ether .beta.-cyclodextrin, also known as
Captisol.RTM.. See, e.g., U.S. Pat. No. 5,376,645. In certain
embodiments, the composition comprises
hexapropyl-.beta.-cyclodextrin. In a more particular embodiment,
the composition comprises hexapropyl-.beta.-cyclodextrin (10-50% in
water).
[0192] The injectable composition can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0193] Generally, the compounds provided herein are administered in
an effective amount. The amount of the compound actually
administered will typically be determined by a physician, in the
light of the relevant circumstances, including the condition to be
treated, the chosen route of administration, the actual compound
administered, the age, weight, response of the individual patient,
the severity of the patient's symptoms, and the like.
[0194] The compositions are presented in unit dosage forms to
facilitate accurate dosing. The term "unit dosage forms" refers to
physically discrete units suitable as unitary dosages for human
subjects and other mammals, each unit containing a predetermined
quantity of active material calculated to produce the desired
therapeutic effect, in association with a suitable pharmaceutical
excipient. Typical unit dosage forms include pre-filled,
pre-measured ampules or syringes of the liquid compositions. In
such compositions, the compound is usually a minor component (from
about 0.1% to about 50% by weight or preferably from about 1% to
about 40% by weight) with the remainder being various vehicles or
carriers and processing aids helpful for forming the desired dosing
form.
[0195] The compounds provided herein can be administered as the
sole active agent, or they can be administered in combination with
other active agents. In one aspect, the present invention provides
a combination of a compound of the present invention and another
pharmacologically active agent. Administration in combination can
proceed by any technique apparent to those of skill in the art
including, for example, separate, sequential, concurrent, and
alternating administration.
[0196] Although the descriptions of pharmaceutical compositions
provided herein are principally directed to pharmaceutical
compositions which are suitable for administration to humans, it
will be understood by the skilled artisan that such compositions
are generally suitable for administration to animals of all sorts.
Modification of pharmaceutical compositions suitable for
administration to humans in order to render the compositions
suitable for administration to various animals is well understood,
and the ordinarily skilled veterinary pharmacologist can design
and/or perform such modification with ordinary experimentation.
General considerations in the formulation and/or manufacture of
pharmaceutical compositions can be found, for example, in
Remington: The Science and Practice of Pharmacy 21.sup.st ed.,
Lippincott Williams & Wilkins, 2005.
Methods of Use and Treatment
[0197] As generally described herein, the present invention is
directed to C21-substituted neuroactive steroids designed, for
example, to act as GABA modulators. In certain embodiments, such
compounds are envisioned to be useful as therapeutic agents for the
inducement of anesthesia and/or sedation in a subject. In some
embodiments, such compounds are envisioned to be useful as
therapeutic agents for treating a CNS-related disorder (e.g., sleep
disorder, a mood disorder such as depression, a schizophrenia
spectrum disorder, a convulsive disorder, a disorder of memory
and/or cognition, a movement disorder, a personality disorder,
autism spectrum disorder, pain, traumatic brain injury, a vascular
disease, a substance abuse disorder and/or withdrawal syndrome, or
tinnitus) in a subject in need (e.g., a subject with Rett syndrome,
Fragile X syndrome, or Angelman syndrome).
[0198] Thus, in one aspect, the present invention provides a method
of inducing sedation and/or anesthesia in a subject, comprising
administering to the subject an effective amount of a compound of
the present invention or a composition thereof. In certain
embodiments, the compound is administered by intravenous
administration.
[0199] Earlier studies (see, e.g., Gee et al., European Journal of
Pharmacology, 136:419-423 (1987)) demonstrated that certain
3.alpha.-hydroxylated steroids are orders of magnitude more potent
as modulators of the GABA receptor complex (GRC) than others had
reported (see, e.g., Majewska et al., Science 232:1004-1007 (1986);
Harrison et al., J Pharmacol. Exp. Ther. 241:346-353 (1987)).
Majewska et al. and Harrison et al. taught that
3.alpha.-hydroxylated-5-reduced steroids are only capable of much
lower levels of effectiveness. In vitro and in vivo experimental
data have now demonstrated that the high potency of these steroids
allows them to be therapeutically useful in the modulation of brain
excitability via the GRC (see, e.g., Gee et al., European Journal
of Pharmacology, 136:419-423 (1987); Wieland et al.,
Psychopharmacology 118(1):65-71 (1995)).
[0200] Various synthetic steroids have also been prepared as
neuroactive steroids. See, for example, U.S. Pat. No. 5,232,917,
which discloses neuroactive steroid compounds useful in treating
stress, anxiety, insomnia, seizure disorders, and mood disorders
such as depression, that are amenable to GRC-active agents, such as
depression, in a therapeutically beneficial manner. Furthermore, it
has been previously demonstrated that these steroids interact at a
unique site on the GRC which is distinct from other known sites of
interaction (e.g., barbiturates, benzodiazepines, and GABA) where
therapeutically beneficial effects on stress, anxiety, sleep, mood
disorders and seizure disorders have been previously elicited (see,
e.g., Gee, K. W. and Yamamura, H. I., "Benzodiazepines and
Barbiturates: Drugs for the Treatment of Anxiety, Insomnia and
Seizure Disorders," in Central Nervous System Disorders, Horvell,
ed., Marcel-Dekker, New York (1985), pp. 123-147; Lloyd, K. G. and
Morselli, P. L., "Psychopharmacology of GABAergic Drugs," in
Psychopharmacology: The Third Generation of Progress, H. Y.
Meltzer, ed., Raven Press, N.Y. (1987), pp. 183-195; and Gee et
al., European Journal of Pharmacology, 136:419-423 (1987). These
compounds are desirable for their duration, potency, and oral
activity (along with other forms of administration).
[0201] Compounds of the present invention, as described herein, are
generally designed to modulate GABA function, and therefore to act
as neuroactive steroids for the treatment and prevention of
CNS-related conditions in a subject. Modulation, as used herein,
refers to the inhibition or potentiation of GABA receptor function.
Accordingly, the compounds and pharmaceutical compositions provided
herein find use as therapeutics for preventing and/or treating CNS
conditions in mammals including humans and non-human mammals. Thus,
and as stated earlier, the present invention includes within its
scope, and extends to, the recited methods of treatment, as well as
to the compounds for such methods, and to the use of such compounds
for the preparation of medicaments useful for such methods.
[0202] Exemplary CNS conditions related to GABA-modulation include,
but are not limited to, sleep disorders [e.g., insomnia], mood
disorders [e.g., depression, dysthymic disorder (e.g., mild
depression), bipolar disorder (e.g., I and/or II), anxiety
disorders (e.g., generalized anxiety disorder (GAD), social anxiety
disorder), stress, post-traumatic stress disorder (PTSD),
compulsive disorders (e.g., obsessive compulsive disorder (OCD))],
schizophrenia spectrum disorders [e.g., schizophrenia,
schizoaffective disorder], convulsive disorders [e.g., epilepsy
(e.g., status epilepticus (SE)), seizures], disorders of memory
and/or cognition [e.g., attention disorders (e.g., attention
deficit hyperactivity disorder (ADHD)), dementia (e.g., Alzheimer's
type dementia, Lewis body type dementia, vascular type dementia],
movement disorders [e.g., Huntington's disease, Parkinson's
disease], personality disorders [e.g., anti-social personality
disorder, obsessive compulsive personality disorder], autism
spectrum disorders (ASD) [e.g., autism, monogenetic causes of
autism such as synaptophathy's, e.g., Rett syndrome, Fragile X
syndrome, Angelman syndrome], pain [e.g., neuropathic pain, injury
related pain syndromes, acute pain, chronic pain], traumatic brain
injury (TBI), vascular diseases [e.g., stroke, ischemia, vascular
malformations], substance abuse disorders and/or withdrawal
syndromes [e.g., addition to opiates, cocaine, and/or alcohol], and
tinnitus.
[0203] In yet another aspect, provided is a combination of a
compound of the present invention and another pharmacologically
active agent. The compounds provided herein can be administered as
the sole active agent or they can be administered in combination
with other agents. Administration in combination can proceed by any
technique apparent to those of skill in the art including, for
example, separate, sequential, concurrent and alternating
administration.
[0204] In another aspect, provided is a method of treating or
preventing brain excitability in a subject susceptible to or
afflicted with a condition associated with brain excitability,
comprising administering to the subject an effective amount of a
compound of the present invention to the subject.
[0205] In yet another aspect, provided is a method of treating or
preventing stress or anxiety in a subject, comprising administering
to the subject in need of such treatment an effective amount of a
compound of the present invention, or a composition thereof.
[0206] In yet another aspect, provided is a method of alleviating
or preventing seizure activity in a subject, comprising
administering to the subject in need of such treatment an effective
amount of a compound of the present invention.
[0207] In yet another aspect, provided is a method of alleviating
or preventing insomnia in a subject, comprising administering to
the subject in need of such treatment an effective amount of a
compound of the present invention, or a composition thereof.
[0208] In yet another aspect, provided is a method of inducing
sleep and maintaining substantially the level of REM sleep that is
found in normal sleep, wherein substantial rebound insomnia is not
induced, comprising administering an effective amount of a compound
of the present invention.
[0209] In yet another aspect, provided is a method of alleviating
or preventing PMS or PND in a subject, comprising administering to
the subject in need of such treatment an effective amount of a
compound of the present invention.
[0210] In yet another aspect, provided is a method of treating or
preventing mood disorders in a subject, comprising administering to
the subject in need of such treatment an effective amount of a
compound of the present invention. In certain embodiments the mood
disorder is depression.
[0211] In yet another aspect, provided is a method of inducing
anesthesia in a subject, comprising administering to the subject an
effective amount of a compound of the present invention.
[0212] In yet another aspect, provided is a method of cognition
enhancement or treating memory disorder by administering to the
subject a therapeutically effective amount of a compound of the
present invention. In certain embodiments, the disorder is
Alzheimer's disease. In certain embodiments, the disorder is Rett
syndrome.
[0213] In yet another aspect, provided is a method of treating
attention disorders by administering to the subject a
therapeutically effective amount of a compound of the present
invention. In certain embodiments, the attention disorder is
ADHD.
[0214] In certain embodiments, the compound is administered to the
subject chronically. In certain embodiments, the compound is
administered to the subject orally, subcutaneously,
intramuscularly, or intravenously.
Anesthesia/Sedation
[0215] Anesthesia is a pharmacologically induced and reversible
state of amnesia, analgesia, loss of responsiveness, loss of
skeletal muscle reflexes, decreased stress response, or all of
these simultaneously. These effects can be obtained from a single
drug which alone provides the correct combination of effects, or
occasionally with a combination of drugs (e.g., hypnotics,
sedatives, paralytics, analgesics) to achieve very specific
combinations of results. Anesthesia allows patients to undergo
surgery and other procedures without the distress and pain they
would otherwise experience.
[0216] Sedation is the reduction of irritability or agitation by
administration of a pharmacological agent, generally to facilitate
a medical procedure or diagnostic procedure.
[0217] Sedation and analgesia include a continuum of states of
consciousness ranging from minimal sedation (anxiolysis) to general
anesthesia.
[0218] Minimal sedation is also known as anxiolysis. Minimal
sedation is a drug-induced state during which the patient responds
normally to verbal commands. Cognitive function and coordination
may be impaired. Ventilatory and cardiovascular functions are
typically unaffected.
[0219] Moderate sedation/analgesia (conscious sedation) is a
drug-induced depression of consciousness during which the patient
responds purposefully to verbal command, either alone or
accompanied by light tactile stimulation. No interventions are
usually necessary to maintain a patent airway. Spontaneous
ventilation is typically adequate. Cardiovascular function is
usually maintained.
[0220] Deep sedation/analgesia is a drug-induced depression of
consciousness during which the patient cannot be easily aroused,
but responds purposefully (not a reflex withdrawal from a painful
stimulus) following repeated or painful stimulation. Independent
ventilatory function may be impaired and the patient may require
assistance to maintain a patent airway. Spontaneous ventilation may
be inadequate. Cardiovascular function is usually maintained.
[0221] General anesthesia is a drug-induced loss of consciousness
during which the patient is not arousable, even to painful stimuli.
The ability to maintain independent ventilatory function is often
impaired and assistance is often required to maintain a patent
airway. Positive pressure ventilation may be required due to
depressed spontaneous ventilation or drug-induced depression of
neuromuscular function. Cardiovascular function may be
impaired.
[0222] Sedation in the intensive care unit (ICU) allows the
depression of patients' awareness of the environment and reduction
of their response to external stimulation. It can play a role in
the care of the critically ill patient, and encompasses a wide
spectrum of symptom control that will vary between patients, and
among individuals throughout the course of their illnesses. Heavy
sedation in critical care has been used to facilitate endotracheal
tube tolerance and ventilator synchronization, often with
neuromuscular blocking agents.
[0223] In some embodiments, sedation (e.g., long-term sedation,
continuous sedation) is induced and maintained in the ICU for a
prolonged period of time (e.g., 1 day, 2 days, 3 days, 5 days, 1
week, 2 week, 3 weeks, 1 month, 2 months). Long-term sedation
agents may have long duration of action. Sedation agents in the ICU
may have short elimination half-life.
[0224] Procedural sedation and analgesia, also referred to as
conscious sedation, is a technique of administering sedatives or
dissociative agents with or without analgesics to induce a state
that allows a subject to tolerate unpleasant procedures while
maintaining cardiorespiratory function.
Anxiety Disorders
[0225] Anxiety disorder is a blanket term covering several
different forms of abnormal and pathological fear and anxiety.
Current psychiatric diagnostic criteria recognize a wide variety of
anxiety disorders.
[0226] Generalized anxiety disorder is a common chronic disorder
characterized by long-lasting anxiety that is not focused on any
one object or situation. Those suffering from generalized anxiety
experience non-specific persistent fear and worry and become overly
concerned with everyday matters. Generalized anxiety disorder is
the most common anxiety disorder to affect older adults.
[0227] In panic disorder, a person suffers from brief attacks of
intense terror and apprehension, often marked by trembling,
shaking, confusion, dizziness, nausea, difficulty breathing. These
panic attacks, defined by the APA as fear or discomfort that
abruptly arises and peaks in less than ten minutes, can last for
several hours and can be triggered by stress, fear, or even
exercise; although the specific cause is not always apparent. In
addition to recurrent unexpected panic attacks, a diagnosis of
panic disorder also requires that said attacks have chronic
consequences: either worry over the attacks' potential
implications, persistent fear of future attacks, or significant
changes in behavior related to the attacks. Accordingly, those
suffering from panic disorder experience symptoms even outside of
specific panic episodes. Often, normal changes in heartbeat are
noticed by a panic sufferer, leading them to think something is
wrong with their heart or they are about to have another panic
attack. In some cases, a heightened awareness (hypervigilance) of
body functioning occurs during panic attacks, wherein any perceived
physiological change is interpreted as a possible life threatening
illness (i.e. extreme hypochondriasis).
[0228] Obsessive compulsive disorder is a type of anxiety disorder
primarily characterized by repetitive obsessions (distressing,
persistent, and intrusive thoughts or images) and compulsions
(urges to perform specific acts or rituals). The OCD thought
pattern may be likened to superstitions insofar as it involves a
belief in a causative relationship where, in reality, one does not
exist. Often the process is entirely illogical; for example, the
compulsion of walking in a certain pattern may be employed to
alleviate the obsession of impending harm. And in many cases, the
compulsion is entirely inexplicable, simply an urge to complete a
ritual triggered by nervousness. In a minority of cases, sufferers
of OCD may only experience obsessions, with no overt compulsions; a
much smaller number of sufferers experience only compulsions.
[0229] The single largest category of anxiety disorders is that of
Phobia, which includes all cases in which fear and anxiety is
triggered by a specific stimulus or situation. Sufferers typically
anticipate terrifying consequences from encountering the object of
their fear, which can be anything from an animal to a location to a
bodily fluid.
[0230] Post-traumatic stress disorder or PTSD is an anxiety
disorder which results from a traumatic experience. Post-traumatic
stress can result from an extreme situation, such as combat, rape,
hostage situations, or even serious accident. It can also result
from long term (chronic) exposure to a severe stressor, for example
soldiers who endure individual battles but cannot cope with
continuous combat. Common symptoms include flashbacks, avoidant
behaviors, and depression.
Neurodegenerative Diseases and Disorders
[0231] The term "neurodegenerative disease" includes diseases and
disorders that are associated with the progressive loss of
structure or function of neurons, or death of neurons.
Neurodegenerative diseases and disorders include, but are not
limited to, Alzheimer's disease (including the associated symptoms
of mild, moderate, or severe cognitive impairment); amyotrophic
lateral sclerosis (ALS); anoxic and ischemic injuries; ataxia and
convulsion (including for the treatment and prevention and
prevention of seizures that are caused by schizoaffective disorder
or by drugs used to treat schizophrenia); benign forgetfulness;
brain edema; cerebellar ataxia including McLeod neuroacanthocytosis
syndrome (MLS); closed head injury; coma; contusive injuries (e.g.,
spinal cord injury and head injury); dementias including
multi-infarct dementia and senile dementia; disturbances of
consciousness; Down syndrome; drug-induced or medication-induced
Parkinsonism (such as neuroleptic-induced acute akathisia, acute
dystonia, Parkinsonism, or tardive dyskinesia, neuroleptic
malignant syndrome, or medication-induced postural tremor);
epilepsy; fragile X syndrome; Gilles de la Tourette's syndrome;
head trauma; hearing impairment and loss; Huntington's disease;
Lennox syndrome; levodopa-induced dyskinesia; mental retardation;
movement disorders including akinesias and akinetic (rigid)
syndromes (including basal ganglia calcification, corticobasal
degeneration, multiple system atrophy, Parkinsonism-ALS dementia
complex, Parkinson's disease, postencephalitic parkinsonism, and
progressively supranuclear palsy); muscular spasms and disorders
associated with muscular spasticity or weakness including chorea
(such as benign hereditary chorea, drug-induced chorea,
hemiballism, Huntington's disease, neuroacanthocytosis, Sydenham's
chorea, and symptomatic chorea), dyskinesia (including tics such as
complex tics, simple tics, and symptomatic tics), myoclonus
(including generalized myoclonus and focal cyloclonus), tremor
(such as rest tremor, postural tremor, and intention tremor) and
dystonia (including axial dystonia, dystonic writer's cramp,
hemiplegic dystonia, paroxysmal dystonia, and focal dystonia such
as blepharospasm, oromandibular dystonia, and spasmodic dysphonia
and torticollis); neuronal damage including ocular damage,
retinopathy or macular degeneration of the eye; neurotoxic injury
which follows cerebral stroke, thromboembolic stroke, hemorrhagic
stroke, cerebral ischemia, cerebral vasospasm, hypoglycemia,
amnesia, hypoxia, anoxia, perinatal asphyxia and cardiac arrest;
Parkinson's disease; seizure; status epilecticus; stroke; tinnitus;
tubular sclerosis, and viral infection induced neurodegeneration
(e.g., caused by acquired immunodeficiency syndrome (AIDS) and
encephalopathies). Neurodegenerative diseases also include, but are
not limited to, neurotoxic injury which follows cerebral stroke,
thromboembolic stroke, hemorrhagic stroke, cerebral ischemia,
cerebral vasospasm, hypoglycemia, amnesia, hypoxia, anoxia,
perinatal asphyxia and cardiac arrest. Methods of treating or
preventing a neurodegenerative disease also include treating or
preventing loss of neuronal function characteristic of
neurodegenerative disorder.
Epilepsy
[0232] Epilepsy is a brain disorder characterized by repeated
seizures over time. Types of epilepsy can include, but are not
limited to generalized epilepsy, e.g., childhood absence epilepsy,
juvenile nyoclonic epilepsy, epilepsy with grand-mal seizures on
awakening, West syndrome, Lennox-Gastaut syndrome, partial
epilepsy, e.g., temporal lobe epilepsy, frontal lobe epilepsy,
benign focal epilepsy of childhood.
Status Epilepticus (SE)
[0233] Status epilepticus (SE) can include, e.g., convulsive status
epilepticus, e.g., early status epilepticus, established status
epilepticus, refractory status epilepticus, super-refractory status
epilepticus; non-convulsive status epilepticus, e.g., generalized
status epilepticus, complex partial status epilepticus; generalized
periodic epileptiform discharges; and periodic lateralized
epileptiform discharges. Convulsive status epilepticus is
characterized by the presence of convulsive status epileptic
seizures, and can include early status epilepticus, established
status epilepticus, refractory status epilepticus, super-refractory
status epilepticus. Early status epilepticus is treated with a
first line therapy. Established status epilepticus is characterized
by status epileptic seizures which persist despite treatment with a
first line therapy, and a second line therapy is administered.
Refractory status epilepticus is characterized by status epileptic
seizures which persist despite treatment with a first line and a
second line therapy, and a general anesthetic is generally
administered. Super refractory status epilepticus is characterized
by status epileptic seizures which persist despite treatment with a
first line therapy, a second line therapy, and a general anesthetic
for 24 hours or more.
[0234] Non-convulsive status epilepticus can include, e.g., focal
non-convulsive status epilepticus, e.g., complex partial
non-convulsive status epilepticus, simple partial non-convulsive
status epilepticus, subtle non-convulsive status epilepticus;
generalized non-convulsive status epilepticus, e.g., late onset
absence non-convulsive status epilepticus, atypical absence
non-convulsive status epilepticus, or typical absence
non-convulsive status epilepticus.
[0235] Compositions described herein can also be administered as a
prophylactic to a subject having a CNS disorder e.g., a traumatic
brain injury, status epilepticus, e.g., convulsive status
epilepticus, e.g., early status epilepticus, established status
epilepticus, refractory status epilepticus, super-refractory status
epilepticus; non-convulsive status epilepticus, e.g., generalized
status epilepticus, complex partial status epilepticus; generalized
periodic epileptiform discharges; and periodic lateralized
epileptiform discharges; prior to the onset of a seizure.
Seizure
[0236] A seizure is the physical findings or changes in behavior
that occur after an episode of abnormal electrical activity in the
brain. The term "seizure" is often used interchangeably with
"convulsion." Convulsions are when a person's body shakes rapidly
and uncontrollably. During convulsions, the person's muscles
contract and relax repeatedly.
[0237] Based on the type of behavior and brain activity, seizures
are divided into two broad categories: generalized and partial
(also called local or focal). Classifying the type of seizure helps
doctors diagnose whether or not a patient has epilepsy.
[0238] Generalized seizures are produced by electrical impulses
from throughout the entire brain, whereas partial seizures are
produced (at least initially) by electrical impulses in a
relatively small part of the brain. The part of the brain
generating the seizures is sometimes called the focus.
[0239] There are six types of generalized seizures. The most common
and dramatic, and therefore the most well known, is the generalized
convulsion, also called the grand-mal seizure. In this type of
seizure, the patient loses consciousness and usually collapses. The
loss of consciousness is followed by generalized body stiffening
(called the "tonic" phase of the seizure) for 30 to 60 seconds,
then by violent jerking (the "clonic" phase) for 30 to 60 seconds,
after which the patient goes into a deep sleep (the "postictal" or
after-seizure phase). During grand-mal seizures, injuries and
accidents may occur, such as tongue biting and urinary
incontinence.
[0240] Absence seizures cause a short loss of consciousness (just a
few seconds) with few or no symptoms. The patient, most often a
child, typically interrupts an activity and stares blankly. These
seizures begin and end abruptly and may occur several times a day.
Patients are usually not aware that they are having a seizure,
except that they may be aware of "losing time."
[0241] Myoclonic seizures consist of sporadic jerks, usually on
both sides of the body. Patients sometimes describe the jerks as
brief electrical shocks. When violent, these seizures may result in
dropping or involuntarily throwing objects.
[0242] Clonic seizures are repetitive, rhythmic jerks that involve
both sides of the body at the same time.
[0243] Tonic seizures are characterized by stiffening of the
muscles.
[0244] Atonic seizures consist of a sudden and general loss of
muscle tone, particularly in the arms and legs, which often results
in a fall.
[0245] Seizures described herein can include epileptic seizures;
acute repetitive seizures; cluster seizures; continuous seizures;
unremitting seizures; prolonged seizures; recurrent seizures;
status epilepticus seizures, e.g., refractory convulsive status
epilepticus, non-convulsive status epilepticus seizures; refractory
seizures; myoclonic seizures; tonic seizures; tonic-clonic
seizures; simple partial seizures; complex partial seizures;
secondarily generalized seizures; atypical absence seizures;
absence seizures; atonic seizures; benign Rolandic seizures;
febrile seizures; emotional seizures; focal seizures; gelastic
seizures; generalized onset seizures; infantile spasms; Jacksonian
seizures; massive bilateral myoclonus seizures; multifocal
seizures; neonatal onset seizures; nocturnal seizures; occipital
lobe seizures; post traumatic seizures; subtle seizures; Sylvan
seizures; visual reflex seizures; or withdrawal seizures.
Equivalents and Scope
[0246] In the claims articles such as "a," "an," and "the" may mean
one or more than one unless indicated to the contrary or otherwise
evident from the context. Claims or descriptions that include "or"
between one or more members of a group are considered satisfied if
one, more than one, or all of the group members are present in,
employed in, or otherwise relevant to a given product or process
unless indicated to the contrary or otherwise evident from the
context. The invention includes embodiments in which exactly one
member of the group is present in, employed in, or otherwise
relevant to a given product or process. The invention includes
embodiments in which more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product
or process.
[0247] Furthermore, the invention encompasses all variations,
combinations, and permutations in which one or more limitations,
elements, clauses, and descriptive terms from one or more of the
listed claims is introduced into another claim. For example, any
claim that is dependent on another claim can be modified to include
one or more limitations found in any other claim that is dependent
on the same base claim. Where elements are presented as lists,
e.g., in Markush group format, each subgroup of the elements is
also disclosed, and any element(s) can be removed from the group.
It should it be understood that, in general, where the invention,
or aspects of the invention, is/are referred to as comprising
particular elements and/or features, certain embodiments of the
invention or aspects of the invention consist, or consist
essentially of, such elements and/or features. For purposes of
simplicity, those embodiments have not been specifically set forth
in haec verba herein. It is also noted that the terms "comprising"
and "containing" are intended to be open and permits the inclusion
of additional elements or steps. Where ranges are given, endpoints
are included. Furthermore, unless otherwise indicated or otherwise
evident from the context and understanding of one of ordinary skill
in the art, values that are expressed as ranges can assume any
specific value or sub-range within the stated ranges in different
embodiments of the invention, to the tenth of the unit of the lower
limit of the range, unless the context clearly dictates
otherwise.
[0248] This application refers to various issued patents, published
patent applications, journal articles, and other publications, all
of which are incorporated herein by reference. If there is a
conflict between any of the incorporated references and the instant
specification, the specification shall control. In addition, any
particular embodiment of the present invention that falls within
the prior art may be explicitly excluded from any one or more of
the claims. Because such embodiments are deemed to be known to one
of ordinary skill in the art, they may be excluded even if the
exclusion is not set forth explicitly herein. Any particular
embodiment of the invention can be excluded from any claim, for any
reason, whether or not related to the existence of prior art.
[0249] Those skilled in the art will recognize or be able to
ascertain using no more than routine experimentation many
equivalents to the specific embodiments described herein. The scope
of the present embodiments described herein is not intended to be
limited to the above Description, but rather is as set forth in the
appended claims. Those of ordinary skill in the art will appreciate
that various changes and modifications to this description may be
made without departing from the spirit or scope of the present
invention, as defined in the following claims.
EXAMPLES
[0250] In order that the invention described herein may be more
fully understood, the following examples are set forth. The
synthetic and biological examples described in this application are
offered to illustrate the compounds, pharmaceutical compositions
and methods provided herein and are not to be construed in any way
as limiting their scope.
Materials and Methods
[0251] The compounds provided herein can be prepared from readily
available starting materials using the following general methods
and procedures. It will be appreciated that where typical or
preferred process conditions (i.e., reaction temperatures, times,
mole ratios of reactants, solvents, pressures, etc.) are given,
other process conditions can also be used unless otherwise stated.
Optimum reaction conditions may vary with the particular reactants
or solvent used, but such conditions can be determined by one
skilled in the art by routine optimization.
[0252] Additionally, as will be apparent to those skilled in the
art, conventional protecting groups may be necessary to prevent
certain functional groups from undergoing undesired reactions. The
choice of a suitable protecting group for a particular functional
group as well as suitable conditions for protection and
deprotection are well known in the art. For example, numerous
protecting groups, and their introduction and removal, are
described in T. W. Greene and P. G. M. Wuts, Protecting Groups in
Organic Synthesis, Second Edition, Wiley, New York, 1991, and
references cited therein.
[0253] The compounds provided herein may be isolated and purified
by known standard procedures. Such procedures include (but are not
limited to) recrystallization, column chromatography, HPLC, or
supercritical fluid chromatography (SFC). The following schemes are
presented with details as to the preparation of representative
heteroaryls and heterocyclyls that have been listed herein. The
compounds provided herein may be prepared from known or
commercially available starting materials and reagents by one
skilled in the art of organic synthesis. Exemplary chiral columns
available for use in the separation/purification of the
enantiomers/diastereomers provided herein include, but are not
limited to, CHIRALPAK.RTM. AD-10, CHIRALCEL.RTM. OB, CHIRALCEL.RTM.
OB-H, CHIRALCEL.RTM. OD, CHIRALCEL.RTM. OD-H, CHIRALCEL.RTM. OF,
CHIRALCEL.RTM. OG, CHIRALCEL.RTM. OJ and CHIRALCEL.RTM. OK.
[0254] The stereochemistry assigned herein (e.g., the assignment of
"R" or "S" to the C21 position of the steroid) may be tentatively
(e.g., randomly) assigned. For example, a C21 position may be drawn
in the "R" configuration when the C21 position is in the "S"
configuration.
[0255] .sup.1H-NMR reported herein (e.g., for intermediates) may be
a partial representation of the full NMR spectrum of a compound,
e.g., a compound described herein. For example, the reported
.sup.1H NMR may exclude the region between .delta. (ppm) of about 1
to about 2.5 ppm.
[0256] Exemplary general method for preparative HPLC: Column:
Waters RBridge prep 10 .quadrature.m C18, 19*250 mm. Mobile phase:
acetonitrile, water (NH.sub.4HCO.sub.3) (30 L water, 24 g
NH.sub.4HCO.sub.3, 30 mL NH.sub.3.H.sub.2O). Flow rate: 25
mL/min
[0257] Exemplary general method for analytical HPLC: Mobile phase:
A: water (10 mM NH.sub.4HCO.sub.3), B: acetonitrile Gradient:
5%-95% B in 1.6 or 2 min Flow rate: 1.8 or 2 mL/min; Column:
XBridge C18, 4.6*50 mm, 3.5 .mu.m at 45 C.
Synthetic Methods
Example 1. Synthesis of 1 and 2
##STR00040##
[0259] To a solution of A1 (500 mg, 1.29 mmol) in THF (4 mL was
added KOH (144 mg, 2.58 mmol) and MeI (200 mg, 1.41 mmol) at
25.degree. C. The mixture was stirred at 25.degree. C. for 2 h.
After TLC showed the starting material was consumed, the reaction
mixture was treated with water (20 mL) and extracted with EtOAc (30
mL.times.2). The organic phase was washed with brine (30 mL), dried
over anhydrous Na.sub.2SO.sub.4, concentrated in vacuum. The
residue was purified by prep-HPLC to afford
(R)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-
-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)propan-1-one
(79.5 mg, 15.4%) and
(S)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-
-1H-cyclopenta[a]phenanthren-17-yl)-2-(2H-1,2,3-triazol-2-yl)propan-1-one
(93.1 mg, 18%) as white solid.
[0260] .sup.1H NMR (1) (400 MHz, CDCl3) .delta. 7.67 (s, 2H),
5.27-5.22 (m, 1H), 2.25-2.23 (m, 1H), 2.11-2.05 (m, 1H), 1.87-1.66
(m, 9H), 1.41-1.02 (m, 19H), 0.65 (s, 3H). LCMS Rt=0.945 min in 1.5
min chromatography, 5-95AB, purity 100%, MS ESI calcd. for
C.sub.24H.sub.38N.sub.3O.sub.2 [M+H].sup.+ 400, found 382
[M+H-18].
[0261] .sup.1H NMR (2) (400 MHz, CDCl3) .delta. 7.66 (s, 2H),
5.42-5.37 (m, 1H), 2.66-2.64 (m, 1H), 2.14-2.11 (m, 2H), 1.83-1.65
(m, 10H), 1.41-1.07 (m, 17H), 0.68 (s, 3H). LCMS Rt=0.922 min in
1.5 min chromatography, 5-95AB, purity 100%, MS ESI calcd. for
C.sub.24H.sub.38N.sub.3O.sub.2 [M+H].sup.+ 400, found 382
[M+H-18].
Example 2. Synthesis of 3 and 4
##STR00041##
[0262] To a solution of A2 (400 mg, 0.976 mmol) in THF (3 mL) was
added KOH (109 mg, 1.95 mmol) and MeI (1.58 g, 11.1 mmol) at
25.degree. C. The mixture was stirred at 25.degree. C. for 2 h.
After TLC showed the starting material was consumed, the reaction
mixture was treated with water (20 mL) and extracted with ELOAc (30
mL.times.2), The organic phase was washed with brine (30 mL), dried
over anhydrous Na.sub.2SO.sub.4, concentrated in vacuum. The
residue was purified by column chromatography on silica gel
(PE/EtOAc=5/1 to EtOAc) to afford
1-((S)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahy-
dro-1H-cyclopenta[a]phenanthren-17-yl)-1-oxopropan-2-yl)-1H-pyrazole-4-car-
bonitrile (100 mg, 24.2%) and
1-((R)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahy-
dro-1H-cyclopenta[a]phenanthren-17-yl)-1-oxopropan-2-yl)-1H-pyrazole-4-car-
bonitrile (139 mg, 33.6%) as a white solid.
[0263] .sup.1H NMR (3) (400 MHz, CDCl.sub.3) .delta. 7.99 (s, 1H),
7.77 (s, 1H), 5.27-5.25 (m, 1H), 2.73-2.71 (m, 1H), 2.18-2.13 (m,
2H), 1.81-1.58 (m, 10H), 1.48-1.07 (m, 17H), 0.56 (s, 3H). LCMS
Rt=0.934 min in 1.5 min chromatography, 5-95AB, purity 100%, MS ESI
calcd. for C.sub.26H.sub.38N.sub.3O.sub.2 [M+H].sup.+ 424, found
406 [M+H-18].
[0264] .sup.1H NMR (4) (400 MHz, CDCl3) .delta. 7.87 (s, 1H), 7.81
(s, 1H), 5.06-5.01 (m, 1H), 2.48 (t, J=8.8 Hz, 1H), 2.09-2.00 (m,
1H), 1.79-1.59 (m, 12H), 1.50-1.07 (m, 16H), 0.66 (s, 3H). LCMS
Rt=0.946 min in 1.5 min chromatography, 5-95AB, purity 100%, MS ESI
calcd. for C.sub.26H.sub.38N.sub.3O.sub.2 [M+H].sup.+ 424, found
406 [M+H-18].
Example 3. Synthesis of 5
##STR00042## ##STR00043##
[0266] Step 1. Synthesis of A4.
[0267] To a solution of 2,6-di-tert-butyl-4-methylphenol (A3, 24 g,
109 mmol) in toluene (100 mL) was added AlMe.sub.3 (2 M in toluene,
27.3 mL, 54.6 mmol) dropwise at 10.degree. C. The mixture was then
stirred at 25.degree. C. for 1 hour. To the mixture was added a
solution of compound
(5R,8R,9R,10S,13S,14S)-13-methyldodecahydro-1H-cyclopenta[a]phenanthrene--
3,17(2H,4H)-dione (5 g, 18.2 mmol) in toluene (50 mL) dropwise at
-70.degree. C. dropwise under N.sub.2. The mixture was stirred at
-70.degree. C. for 1 hour. MeMgBr (3 M in ether, 18.2 mL, 54.6
mmol) was added dropwise at -70.degree. C. The mixture was stirred
at -70.degree. C. for another 3 hours. TLC showed the reaction was
completed. The mixture was poured into citric acid (150 mL, 20%
aq.). The mixture was extracted with EtOAc (100 mL*2). The combined
organic layer was concentrated under vacuum, purified by column
chromatography on silica gel (petroleum ether:EtOAc=50:1 to 1:1) to
give
(3R,5R,8R,9R,10S,13S,14S)-3-hydroxy-3,13-dimethyltetradecahydro-1H-cyclop-
enta[a]phenanthren-17(2H)-one (4.8 g, 90%) as a white solid.
[0268] .sup.1H NMR (A4) (400 MHz, CDCl.sub.3) .delta. 2.50-2.35 (m,
1H), 2.14-2.01 (m, 1H), 1.96-1.00 (m, 25H), 0.85 (s, 3H).
[0269] Step 2. Synthesis of A5.
[0270] To a suspension of PPh.sub.3PrBr (19 g, 49.5 mmol) in THF
(100 mL) was added t-BuOK (5.5 g, 49.5 mmol) at 25.degree. C. The
color of the suspension was turned to dark red. After stirring at
60.degree. C. for 1 h,
(3R,5R,8R,9R,10S,13S,14S)-3-hydroxy-3,13-dimethyltetradecahydro-1H-cyc-
lopenta[a]phenanthren-17(2H)-one (4.8 g, 16.5 mmol) was added at
60.degree. C. The reaction mixture was stirred at 60.degree. C. for
16 h. TLC showed the reaction was completed. To the reaction
mixture was added water (50 mL) and EtOAc (100 mL). The color of
the mixture was turned to light yellow. The organic layer was
separated. The aqueous phase was extracted with EtOAc (100 mL). The
combined organic layer was concentrated in vacuum, purified by
column chromatography on silica gel (PE:EtOAc=100:1 to 20:1) to
give
(3R,5R,8R,9R,10S,13S,14S,Z)-3,13-dimethyl-17-propylidenehexadecahydro-1H--
cyclopenta[a]phenanthren-3-ol (1.6 g, 30%) as colorless oil.
[0271] .sup.1H NMR (A5) (400 MHz, CDCl.sub.3) .delta. 5.06-4.95 (m,
1H), 2.42-2.32 (m, 1H), 2.26-2.00 (m, 4H), 1.90-1.05 (m, 21H),
1.00-0.85 (m, 9H).
[0272] Step 3. Synthesis of A6.
[0273] To a solution of
(3R,5R,8R,9R,10S,13S,14S)-3,13-dimethyl-17-propylidenehexadecahydro-1H-cy-
clopenta[a]phenanthren-3-ol (1.6 g, 5.05 mmol) in THF (5 mL) was
added BH.sub.3-Me.sub.2S (2.5 mL, 25 mmol) at 0.degree. C.
dropwise. The solution was stirred at 25.degree. C. for 16 h. TLC
(PE/EtOAc=5/1) showed the reaction was completed. After cooling to
0.degree. C., NaOH (10%, 10 mL, aq.) was added very slowly. After
the addition was complete, H.sub.2O.sub.2 (30%, 10 mL, aq.) was
added slowly and the inner temperature was maintained below
10.degree. C. The resulting solution was stirred at 25.degree. C.
for 1 h. The mixture was extracted with EtOAc (50*2 mL). The
combined organic layer was separated, washed with
Na.sub.2S.sub.2O.sub.3 (500 mL, 20%, aq.), dried over
Na.sub.2SO.sub.4 and concentrated in vacuum to give
(3R,5R,8R,9R,10S,13S,14S,17S)-17-(1-hydroxypropyl)-3,13-dimethylhexadecah-
ydro-1H-cyclopenta[a]phenanthren-3-ol (1.6 g, 95%) as light yellow
solid.
[0274] .sup.1H NMR (A6) (400 MHz, CDCl.sub.3) .delta. 3.55-3.45 (m,
1H), 1.95-0.60 (m, 37H).
[0275] Step 4. Synthesis of A7.
[0276] To a solution of
(3R,5R,8R,9R,10S,13S,14S,17S)-17-(1-hydroxypropyl)-3,13-dimethylhexadecah-
ydro-1H-cyclopenta[a]phenanthren-3-ol (1.6 g, 4.8 mmol) in DCM (20
mL), was added silica gel (4 g) and PCC (2 g, 9.6 mmol). The
mixture was stirred at 25.degree. C. for 3 h. TLC showed the
reaction was completed. The mixture was filtered and the filter
cake was washed with DCM (20 mL). The combined filtrate was
concentrated in vacuum, purified by column chromatography on silica
gel column eluted with PE/EtOAc=10/1 to 8/1 to give
1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydr-
o-1H-cyclopenta[a]phenanthren-17-yl)propan-1-one (0.5 g, 31%) as
light yellow solid.
[0277] .sup.1H NMR (A7) (400 MHz, CDCl.sub.3) .delta. 2.58-2.50 (m,
1H), 2.44-2.30 (m, 2H), 2.25-2.11 (m, 1H), 2.00-1.91 (m, 1H),
1.88-1.57 (m, 8H), 1.50-0.99 (m, 20H), 0.59 (s, 3H). LCMS (A7)
Rt=1.315 min in 2 min chromatography, 10-80AB, purity 100%, MS ESI
calcd. for C22H37O2 [M+H].sup.+ 333, found 315
([M+H-18].sup.+).
[0278] Step 5. Synthesis of A8.
[0279] To a solution of
1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H--
cyclopenta[a]phenanthren-17-yl)propan-1-one (0.5 g, 1.5 mmol) in
MeOH (5 mL) was added HBr (0.01 mL, 48% in water). Br.sub.2 (149
uL, 3 mmol) was added at 25.degree. C. The reaction mixture was
stirred at 25.degree. C. for 16 h. LCMS showed the reaction was
completed. To the mixture was added Na.sub.2SO.sub.3 (10%, 10 mL,
aq.) and extracted with EtOAc (50 mL*2). The combined organic layer
was dried over Na.sub.2SO.sub.4, concentrated under vacuum to give
2-bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecah-
ydro-1H-cyclopenta[a]phenanthren-17-yl)propan-1-one (0.6 g, 97%) as
a colorless oil.
[0280] .sup.1H NMR (A8) (400 MHz, CDCl.sub.3) .delta. 4.48-4.35 (m,
1H), 3.12-2.70 (m, 1H), 2.40-1.00 (m, 30H), 0.75-0.60 (m, 3H).
[0281] Step 6. Synthesis of 5.
[0282] To a solution of
2-bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecah-
ydro-1H-cyclopenta[a]phenanthren-17-yl)propan-1-one (200 mg, 0.49
mmol) in acetone (2 mL) was added morpholine (200 mg, 2.29 mmol).
After stirring at 25.degree. C. for 16 h, LCMS showed the reaction
was completed. The reaction mixture was in vacuum to give the crude
product which was purified by prep-HPLC to give
1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H--
cyclopenta[a]phenanthren-17-yl)-2-morpholinopropan-1-one, HCl salt
(8.7 mg, 4.3%) as a light yellow solid.
[0283] .sup.1H NMR (5) (400 MHz, methanol-d4) .delta. 4.45-4.20 (m,
1H), 4.15-4.00 (m, 2H), 3.95-3.80 (m, 2H), 3.55-3.45 (m, 1H),
3.30-3.20 (m, 2H), 3.02-2.65 (m, 1H), 2.25-2.10 (m, 2H), 2.00-1.75
(m, 8H), 1.75-1.25 (m, 17H), 1.25-1.10 (m, 3H), 0.90-0.70 (m, 3H).
LCMS (5) Rt=1.972 min in 3 min chromatography, 10-80CD, purity
100%, MS ESI calcd. for C.sub.26H.sub.44NO.sub.3 [M+H].sup.+ 418,
found 418.
Example 4. Synthesis of 6 and 7
##STR00044##
[0285] Step 1.
[0286] To a solution of A9 (500 mg, 1.25 mmol) in acetone (3 mL)
was added 2H-benzo[d][1,2,3]triazole (222 mg, 1.87 mmol) at
25.degree. C. and stirred at this temperature for 12 h. After TLC
showed the starting material was consumed completely, the mixture
was filtrated and the filtrate was concentrated in vacuum. The
residue was purified by column chromatography on silica gel
(PE/EtOAc=3/1 to 1/1) to afford A10 (200 mg, purity=60%) and A11
(400 mg, purity=70%) as white solid.
[0287] .sup.1H NMR (A10): (400 MHz, CDCl3) .delta. 7.87 (dd,
J.sub.1=2.8 Hz, J.sub.2=6.4 Hz, 2H), 7.39 (dd, J.sub.1=2.8 Hz,
J.sub.2=6.4 Hz, 2H), 5.56-5.51 (m, 2H), 2.69-2.65 (m, 1H),
2.23-2.16 (m, 2H), 1.87-1.60 (m, 11H), 1.45-1.01 (m, 66H), 0.87-075
(m, 25H)
[0288] .sup.1H NMR (A11): (400 MHz, CDCl.sub.3) .delta. 8.06 (d,
J=8 Hz, 1H), 7.50-7.46 (m, 1H), 1.82-1.63 (m, 7H), 1.45-1.11 (m,
33H), 0.87-0.82 (m, 6H), 0.72 (s, 3H)
[0289] Step 2.
[0290] To a solution of A10 (200 mg, 0.459 mmol) in THF (3 mL) was
added KOH (51.3 mg, 0.918 mmol) and MeI (1.14 g, 8.03 mmol) at
25.degree. C. The mixture was stirred at 25.degree. C. for 2 h.
After TLC showed the starting material was consumed, the reaction
mixture was treated with water (20 mL) and extracted with EtOAc (30
mL.times.2). The organic phase was washed with brine (30 mL), dried
over anhydrous Na.sub.2SO.sub.4, concentrated in vacuum. The
residue was purified by prep-HPLC to afford
(S)-2-(2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-
-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)prop-
an-1-one (9.3 mg, 4.51%) and
(R)-2-2H-benzo[d][1,2,3]triazol-2-yl)-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3--
hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)propa-
n-1-one (6.1 mg, 2.96%) as white solid.
[0291] .sup.1H NMR (6): (400 MHz, CDCl.sub.3) .delta. 7.90 (dd,
J.sub.1=3.2 Hz, J.sub.2=6.4 Hz, 2H), 7.41 (dd, J.sub.1=2.8 Hz,
J.sub.2=6.4 Hz, 2H), 5.52-5.50 (m, 1H), 2.28-2.25 (m, 2H),
1.82-1.58 (m, 10H), 1.40-1.21 (m, 15H), 1.03-0.86 (m, 3H), 0.68 (s,
3H). LCMS Rt=1.014 min in 1.5 min chromatography, 5-95AB, purity
95%, MS ESI calcd. for C.sub.28H.sub.40N.sub.3O.sub.2 [M+H].sup.+
450, found 432 [M+H-18].
[0292] .sup.1H NMR (7): (400 MHz, CDCl3) .delta. 7.88 (dd,
J.sub.1=3.2 Hz, J.sub.2=6.4 Hz, 2H), 7.38 (dd, J.sub.1=3.2 Hz,
J.sub.2=6.4 Hz, 2H), 5.69-5.68 (m, 1H), 2.72-2.70 (m, 1H),
2.20-1.63 (m, 13H), 1.44-1.08 (m, 16H), 072 (s, 3H). LCMS Rt=0.991
min in 1.5 min chromatography, 5-95AB, purity 95%, MS ESI calcd.
for C.sub.28H.sub.40N.sub.3O.sub.2 [M+H].sup.+ 450, found 432
[M+H-18].
Example 5. Synthesis of 8 and 9
##STR00045## ##STR00046##
[0294] Step 1. Synthesis of A12-A.
[0295] To a solution of compound A3 (274 mg, 1 mmol) in methanol (4
mL) was added iodine (25.4 mg, 0.1 mmol). After stirring at
60.degree. C. for 12 h, TLC showed no compound 2 remained and the
solvent was removed in vacuo. The crude product was dissolved in
dichloromethane (20 mL) and washed with saturated NaHCO.sub.3 (15
mL), brine (15 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was purified by chromatography
on basic alumina (petroleum ether/EtOAc=9:1) to give compound A12-A
(280 mg, 88%) as a white solid.
[0296] .sup.1H NMR (A11): (400 MHz, CDCl.sub.3), .delta. (ppm),
3.19 (s, 3H), 3.13 (s, 3H), 3.18-3.13 (dd, 1H, J=19.2, 8.8 Hz),
0.83 (s, 3H).
[0297] Step 2. Synthesis of A12.
[0298] A solution of CH.sub.3CH.sub.2CH.sub.2PPh.sub.3I (20.2 g, 47
mmol) and KOtBu (4.9 g, 43.6 mmol) in THF (40 mL) was heated to
reflux for 1 h. Then compound A11 (5 g, 15.6 mmol) was added. The
resulting solution was refluxed overnight, then TLC showed the
reaction was complete. The reaction was cooled to room temperature
and quenched with NaHCO.sub.3 (60 mL), the resulting solution was
extracted with EtOAc (30 mL.times.3). The organic layer was washed
with brine (30 mL), dried over Na.sub.2SO.sub.4 and concentrated in
vacuo to give crude compound A12 (30 g, crude) which was used in
the next step without further purification.
[0299] Step 3. Synthesis of A13.
[0300] To a solution of compound A12 (30 g, crude) in THF (40 mL)
was added aqueous HCl (12 M, 5 mL) and stirred at room temperature
for 30 min, then TLC showed the reaction was complete. The solution
was concentrated in vacuo. The residue was purified by column
chromatography (silica gel, EtOAc/PE=1:10) to give compound A13
(3.7 g, 80%, two steps yield) as a white solid.
[0301] .sup.1H NMR: (500 MHz, CDCl.sub.3), .delta. (ppm), 5.06 (t,
1H, J=7.5 Hz), 2.63 (t, 1H, J=14 Hz), 0.96 (t, 3H, J=7.5 Hz), 0.93
(s, 3H).
[0302] Step 4. Synthesis of A14.
[0303] To a solution of compound A13 (1.5 g, 5 mmol) in THF (15 mL)
was added TMSCF.sub.3 (850 mg, 6 mmol) and TBAF (130 mg, 0.5 mmol)
at room temperature. The reaction mixture was stirred at room
temperature for 4 h. Then TBAF (1M in THF, 10 mL) was added and
stirred at room temperature for 30 min. TLC showed the reaction was
complete. The reaction solution was concentrated and the residue
was diluted with EtOAc (40 mL). The resulting solution was washed
with brine (20 mL.times.2), dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The residue was purified by column
chromatography (silica gel, EtOAc/PE=1:10) to give A14 (1.3 g, 70%)
as a white solid.
[0304] .sup.1H NMR (A14): (500 MHz, CDCl.sub.3), .delta. (ppm),
5.05-5.02 (m, 1H), 0.96 (t, 3H, J=7.5 Hz), 0.90 (s, 3H).
[0305] Step 5. Synthesis of A15.
[0306] To a solution of compound A14 (200 mg, 0.54 mmol) in
anhydrous THF (5 mL) was added borane-tetrahydrofuran complex (1.0
M solution in THF, 2 mL, 2 mmol). After stirring at room
temperature for 1 hour, the reaction mixture was cooled in an ice
bath then quenched slowly with 10% aqueous NaOH (1 mL) followed 30%
aqueous solution of H.sub.2O.sub.2 (1.2 mL). The mixture was
allowed to stir at room temperature for 1 hour then extracted with
EtOAc (3.times.10 mL). The combined organic layers were washed with
10% aqueous Na.sub.2S.sub.2O.sub.3 (10 mL), brine (10 mL), dried
over MgSO.sub.4, filtered and concentrated to afford 7 (260 mg,
crude) as white solid which was used in the next step without
further purification.
[0307] Step 6. Synthesis of A16.
[0308] To a solution of compound A15 (300 mg, crude) was dissolved
in 10 mL DCM was added Dess-Martin periodinate (980 mg, 2.31 mmol)
and stirred at room temperature overnight. Then TLC showed the
reaction was complete. The reaction was then filtered through a
plug of celite and the filtrate was concentrated. The residue was
purified by column chromatography (silica gel, EtOAc/PE=1:6) to
give compound A16 (210 mg, 70%) as a white solid.
[0309] .sup.1H NMR: (500 MHz, CDCl.sub.3), .delta. (ppm), 2.56 (t,
3H, J=9 Hz), 1.06 (t, 3H, J=7.3 Hz), 0.63 (s, 3H).
[0310] Step 7. Synthesis of A17 and A18.
[0311] To a solution of compound A16 (500 mg, 1.29 mmol) in MeOH
(10 mL) was added 5 drops of HBr (48%) followed by bromine (1029
mg, 6.45 mmol). After stirring at room temperature for 2 h, the
reaction mixture was poured into ice-water (20 mL) then the
resulting mixture was extracted with EtOAc (15 mL.times.3), The
combined organic layers were washed with brine (20 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated, the residue was
purified by column chromatography (silica gel, EtOAc/PE=1:8) to
give A17 (210 mg, 35%) and A18 (250 mg, 41%) as a white solid.
[0312] .sup.1H NMR: (A17): (500 MHz, CDCl.sub.3), .delta. (ppm)
4.46-4.42 (q, 1H, J=7 Hz), 2.79 (t, 1H, J=9.5 Hz), 1.73 (d, 3H, J=7
Hz), 0.76 (s, 3H).
[0313] .sup.1H NMR: (A18): (500 MHz, CDCl.sub.3), .delta. (ppm),
4.42-4.38 (q, 1H, J=6.5 Hz), 3.11 (t, 1H, J=9 Hz), 1.72 (d, 3H,
J=6.5 Hz), 0.63 (s, 3H).
[0314] Step 8. Synthesis of 8.
[0315] To a solution of compound A17 (50 mg, 0.11 mmol) and
Cs.sub.2CO.sub.3 (720 mg, 2.20 mmol) in THF (3 mL) was added
1H-pyrazole (150 mg, 2.2 mmol). The reaction mixture was heated at
30.degree. C. and stirred overnight. LCMS showed the reaction was
complete and the reaction mixture was diluted with EtOAc (20 mL),
washed with brine (10 mL), dried over Na.sub.2SO.sub.4, filtered,
and concentrated. The residue was purified by Prep-HPLC to give
compound 8 as a white solid.
[0316] .sup.1H NMR (8): (500 MHz, CDCl.sub.3), .delta. (ppm), 7.58
(d, 1H, J=2 Hz), 7.54 (d, 1H, J=1.5 Hz), 6.35 (t, 1H, J=4.5 Hz),
5.23 (q, 1HJ=7.5 Hz), 2.69 (t, 1H, J=9 Hz), 1.67 (d, 3H, J=7 Hz),
0.63 (s, 3H).
Example 6. Synthesis of 10 and 11
##STR00047##
[0318] To a solution of A11 (400 mg, 0.918 mmol) in THF (5 mL) was
added KOH (102 mg, 1.83 mmol) and MeI (156 mg, 1.10 mmol) at
25.degree. C. The mixture was stirred at 25.degree. C. for 2 h.
After TLC showed the starting material was consumed, the reaction
mixture was treated with water (20 mL) and extracted with EtOAc (30
mL.times.2). The organic phase was washed with brine (30 mL), dried
over anhydrous Na.sub.2SO.sub.4, concentrated in vacuum. The
residue was purified by prep-HPLC to afford compound 10 (63.3 mg,
15%) and compound 11 (33.4 mg, 8%) as off white solids.
[0319] .sup.1H NMR (10): (400 MHz, CDCl.sub.3) .delta. 8.09 (d,
J=8.0 Hz, 1H), 7.48-7.41 (m, 1H), 7.39-7.37 (m, 2H), 5.62-5.60 (m,
1H), 2.34 (t, J=9.2 Hz 1H), 2.15-2.00 (m, 1H), 1.79-1.60 (m, 11H),
1.39-1.21 (m, 14H), 1.02-0.99 (m, 3H), 0.67 (s, 3H). LCMS Rt=0.972
min in 1.5 min chromatography, MS ESI calcd. for
C.sub.28H.sub.40N.sub.3O.sub.2 [M+H].sup.+ 450, found 450.
[0320] .sup.1H NMR (11): (400 MHz, CDCl.sub.3) .delta. 8.07 (d,
J=8.0 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.49-7.45 (m, 1H), 7.38-7.36
(m, 1H), 5.79-5.77 (m, 1H), 2.70-2.69 (m, 1H), 2.03-1.91 (m, 2H),
1.89-1.66 (m, 9H), 1.39-1.20 (m, 15H), 1.07-0.99 (m, 3H), 0.62 (s,
3H). LCMS Rt=0.954 min in 1.5 min chromatography, MS ESI calcd. for
C.sub.28H.sub.40N.sub.3O.sub.2 [M+H].sup.+ 450, found 450.
Example 7. Synthesis of 12 and 13
##STR00048## ##STR00049##
[0322] Step 1. Synthesis of A20.
[0323] To a suspension of EtPPh.sub.3Br (17.8 g, 48.2 mmol) in THF
(60 mL) was added t-BuOK (5.40 g, 48.2 mmol). After stirring at
60.degree. C. for 1 h, A19 (2.8 g, 9.64 mmol) was added in portions
at 60.degree. C. The reaction mixture was stirred at the same
temperature for 8 h. TLC (PE/EtOAc=3/1) showed the reaction was
complete, and a main product was found with lower polarity. The
reaction mixture was quenched with aq.NH.sub.4Cl (50 mL) and
extracted with EtOAc (50 mL.times.3) for three times. The combined
organic layer was washed with brine (50 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuum to give the crude
product. The crude product was purified by column chromatography
(PE:EA=10:1-6:1) to give A20 (2.6 g, 89%) as an off white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 5.15-5.10 (m, 1H),
2.42-2.12 (m, 3H), 1.75-0.95 (m, 26H), 0.90 (s, 3H), 0.79-0.62 (m,
2H).
[0324] Step 2. Synthesis of A21.
[0325] To a solution of A20 (2.6 g, 8.59 mmol) in THF (20 mL) was
added dropwise a solution of BH.sub.3-Me.sub.2S (8.59 mL, 10 M) at
0.degree. C. The solution was stirred at 25.degree. C. for 8 h. TLC
(PE:EtOAc=3:1) showed the reaction was almost complete, and a main
product was found with higher polarity. After cooling to 0.degree.
C., a solution of NaOH (34.3 mL, 3M) was added very slowly. After
the addition, H.sub.2O.sub.2 (15.5 mL, 33%) was added slowly and
the inner temperature was maintained below 10.degree. C. The
resulting solution was stirred at 25.degree. C. for 2 h. The
resulting solution was extract with EtOAc (20 mL.times.3). The
combined organic solution was washed with saturated aqueous
Na.sub.2S.sub.2O.sub.3 (20 mL.times.2), brine (20 mL), dried over
Na.sub.2SO.sub.4 and concentrated in vacuum to give the crude
product A21 (3 g, crude) as a solid. The crude product was used for
the next step without further purification.
[0326] Step 3. Synthesis of A22.
[0327] A mixture of A21 (3 g, 9.36 mmol), PCC (3.01 g, 14.0 mmol)
and silica gel (3.31 g, w/w=1/1.1) in DCM (50 mL) was stirred at
25.degree. C. for 2 h, the reaction mixture color became brown. TLC
(PE/EtOAc=3/1) showed the reaction was complete, and a main product
was found with lower polarity. The solution was filtered and the
filter cake was washed with DCM (20 mL). The combined filtrate was
concentrated in vacuum. The residue was purified by silica gel
column eluted with PE/EtOAc=15/1 to 6/1 to give A22 (2.3 g, 77%) as
an off white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
2.59-2.51 (m, 1H), 2.22-2.12 (m, 4H), 2.06-1.97 (m, 1H), 1.88-0.95
(m, 23H), 0.80-0.62 (m, 5H).
[0328] Step 4. Synthesis of A23.
[0329] To a solution of A22 (2.3 g, 7.22 mmol) and a catalytic
amount of concentrated HBr (28.9 mg, 40% in water) in MeOH (20 mL)
was added dropwise dibromine (1.27 g, 7.94 mmol) at 0.degree. C.
The reaction mixture was stirred at 25.degree. C. for 2 h. TLC
(PE:EtOAc=3:1) showed the reaction was complete. The reaction was
quenched by saturated aqueous NaHCO.sub.3 and the pH was adjusted
to 7.about.8. The reaction mixture was extracted with DCM (20
mL.times.2). The combined organic layer was washed with brine (20
mL), dried over Na.sub.2SO.sub.4 and concentrated to get the crude
product A23 (2.6 g, 91%) as an off white solid. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 3.98-3.90 (m, 2H), 2.89-2.81 (m, 1H),
2.26-2.15 (m, 1H), 1.98-0.95 (m, 24H), 0.81-0.62 (m, 5H).
[0330] Step 5. Synthesis of A24.
[0331] To a solution of A23 (300 mg, 754 .mu.mol) in acetone (10
mL) was added K.sub.2CO.sub.3 (155 mg, 1.13 mmol) and
1H-pyrazole-4-carbonitrile (84.1 mg, 904 .mu.mol). The mixture was
stirred at 25.degree. C. for 4 hours. TLC (PE/EA=3/1) showed the
starting material was consumed completely. The solvent was removed
by rotary evaporator. To the mixture was added water (10 mL) and
ethyl acetate (10 mL). The organic layer was separated. The aqueous
phase was extracted with ethyl acetate (10 mL.times.2). The
combined organic layers was washed with brine (10 mL), dried over
Na.sub.2SO.sub.4 and concentrated to give the crude product A24
(350 mg) as an off white solid. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.88 (s, 1H), 7.84 (s, 1H), 5.06-4.90 (m, 2H), 2.68-2.59
(m, 1H), 2.28-1.98 (m, 1H), 1.92-1.01 (m, 24H), 0.82-0.65 (m,
5H).
[0332] Step 5. Synthesis of 12 and 13.
[0333] To a solution of A24 (400 mg, 976 .mu.mol) in THF (10 mL)
was added KOH (81.7 mg, 1.46 mmol) and MeI (207 mg, 1.46 mmol) at
25.degree. C. The mixture was stirred at 25.degree. C. for 2 h.
After LCMS showed the starting material was consumed, the reaction
mixture was treated with water (20 mL) and extracted with EtOAc (20
mL.times.2). The organic phase was washed with brine (20 mL), dried
over anhydrous Na.sub.2SO.sub.4, concentrated in vacuum. The
residue was purified by prep-HPLC to afford both compound 12 (61
mg, 14.7%) and compound 13 (43 mg, 10.4%) as off white solids.
[0334] .sup.1H NMR (12): (400 MHz, CDCl.sub.3) .delta. 8.01 (s,
1H), 7.79 (s, 1H), 5.32-5.27 (m, 1H), 2.78-2.74 (m, 1H), 2.21-2.15
(m, 2H), 1.92-0.98 (m, 26H), 0.79-0.65 (m, 2H), 0.61 (s, 3H). LCMS
Rt=0.960 min in 1.5 min chromatography, MS ESI calcd. for
C.sub.26H.sub.37N.sub.3O.sub.2 [M+H].sup.+ 424, found 424.
[0335] .sup.1H NMR (13) (400 MHz, CDCl.sub.3) .delta. 7.89 (s, 1H),
7.83 (s, 1H), 5.09-5.04 (m, 1H), 2.55-2.49 (m, 1H), 2.16-2.05 (m,
2H), 1.91-0.95 (m, 26H), 0.78-0.60 (m, 5H). LCMS Rt=0.968 min in
1.5 min chromatography, MS ESI calcd. for
C.sub.26H.sub.37N.sub.3O.sub.2 [M+H].sup.+ 424, found 406
[M+H-18].sup.+.
Example 8. Synthesis of 14 and 15
##STR00050##
[0337] Step 1. Synthesis of A24 and A25.
[0338] To a solution of A23 (400 mg, 1 mmol, 1.00 eq) in acetone
(5.00 mL) was added K.sub.2CO.sub.3 (276 mg, 2 mmol, 2 eq) and
2H-1,2,3-triazole (103 mg, 1.5 mmol, 1.5 eq). The mixture was
stirred at 25.degree. C. for 12 hours, until TLC showed the
reaction was complete. The reaction was quenched by water (30 mL)
and then extracted with EA (30 mL*2). The combined organic phase
was washed with saturated brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated in vacuum. The residue
was purified by silica gel chromatography (petroleum ether/ethyl
acetate=3/1 to EA) to afford compound A24 (125 mg, 31% yield) and
compound A25 (185 mg, 45% yield) as solids.
[0339] .sup.1H NMR (A24): (CDCl.sub.3, 400 MHz) .delta. 7.71 (s,
2H), 5.26 (d, J=5.27 Hz, 2H), 2.66-2.56 (m, 1H), 2.30-2.05 (m, 2H),
1.94-1.84 (m, 1H), 1.83-1.64 (m, 6H), 1.50-0.96 (m, 25H), 0.94-0.82
(m, 3H), 0.80-0.67 (m, 6H).
[0340] .sup.1H NMR (A25): (CDCl.sub.3, 400 MHz) .delta. 7.78 (s,
1H), 7.66 (s, 1H), 5.34-5.09 (m, 2H), 2.76-2.63 (m, 1H), 2.32-2.06
(m, 2H), 1.96-1.65 (m, 7H), 1.57-1.47 (m, 2H), 1.23 (m, 17H),
0.90-0.74 (m, 3H), 0.70 (s, 3H).
[0341] Step 2. Synthesis of 14 and 15.
[0342] To a solution of A24 (125 mg, 324 umol, 1.00 eq) and KOH
(36.3 mg, 648 umol, 2 eq) in THF (3.00 mL) was added CH.sub.3I (55
mg, 388 umol, 1.2 eq). The mixture was stirred at 25.degree. C. for
16 hrs until TLC analysis showed the reaction was complete. The
reaction was quenched with water and extracted with EA (2*30 mL),
the combined organic phase was washed with brine and dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by prep-HPLC (0.05% HCl) to afford compound 14 (27.4 mg,
21% yield) and compound 15 (24.9 mg, 19% yield) as off white
solids.
[0343] .sup.1H NMR (14) (CDCl.sub.3 400 MHz) .delta. 7.67 (s, 2H),
5.30-5.21 (m, 1H), 2.31-2.22 (m, 1H), 2.18-2.05 (m, 1H), 1.90-1.71
(m, 3H), 1.70-1.49 (m, 11H), 1.39-1.22 (m, 3H), 1.20 (s, 3H),
1.12-0.89 (m, 7H), 0.67 (s, 3H), 0.65-0.62 (m, 2H). LCMS Rt=1.168
min in 2 min chromatography, MS ESI calcd. for
C.sub.24H.sub.37N.sub.3O.sub.2 [M+H].sup.+ 400, found 382
[M+H-18].
[0344] .sup.1H NMR (15) (CDCl.sub.3, 400 MHz) .delta. 7.67 (s, 2H),
5.47-5.36 (m, 1H), 2.71-2.61 (m, 1H), 2.18-2.06 (m, 2H), 1.86-1.83
(m, 4H), 1.79-1.72 (m, 1H), 1.69-1.64 (m, 4H), 1.60-1.51 (m, 2H),
1.42-1.28 (m, 4H), 1.25-1.19 (m, 6H), 1.17-0.9 (m, 6H), 0.75-0.66
(m, 5H). LCMS Rt=1.134 min in 2 min chromatography, MS ESI calcd.
for C.sub.24H.sub.37N.sub.3O.sub.2 [M+H].sup.+ 400, found 382
[M+H-18].
Example 9. Synthesis of 16 and 17
##STR00051##
[0346] To a solution of A25 (185 mg, 479 umol, 1.00 eq) and KOH
(53.7 mg, 958 umol, 2 eq) in THF (3.00 mL) was added CH3I (81.4 mg,
574 umol, 1.2 eq). The mixture was stirred at 25.degree. C. for 5
hrs until TLC showed the reaction was complete. Then, the reaction
was quenched with water and extracted with EA (2*30 mL), the
combined organic phase was washed with brine and dried over Na2SO4,
filtered and concentrated. The residue was purified by prep-HPLC
(0.05% HCl) to afford compound 16 (18.5 mg, 10% yield) and compound
17 (31.4 mg, 16% yield) as off white solids.
[0347] .sup.1H NMR (16) (CDCl.sub.3, 400 MHz) .delta. 7.75 (s, 1H),
7.59 (s, 1H), 5.52-5.42 (m, 1H), 2.60-2.52 (m, 1H), 2.13-2.00 (m,
1H), 1.94-1.81 (m, 2H), 1.77-1.53 (m, 12H), 1.48-1.39 (m, 1H),
1.38-1.23 (m, 3H), 1.21-1.19 (m, 3H), 1.18-1.03 (m, 5H), 1.02-0.89
(m, 2H), 0.73-0.65 (m, 5H). LCMS Rt=1.054 min in 2 min
chromatography, MS ESI calcd. for C.sub.24H.sub.37N.sub.3O.sub.2
[M+H].sup.+ 400, found 422 [M+23].
[0348] .sup.1H NMR (17) (CDCl.sub.3, 400 MHz) .delta.7.80 (s, 1H),
7.75 (s, 1H), 5.70-5.62 (m, 1H), 2.83-2.76 (m, 1H), 2.24-2.14 (m,
2H), 1.91-1.82 (m, 1H), 1.78-1.65 (m, 8H), 1.59-1.45 (m, 5H),
1.40-1.30 (m, 2H), 1.28-1.23 (m, 2H), 1.21 (s, 3H), 1.16-0.94 (m,
6H), 0.80-0.61 (m, 2H), 0.54 (s, 3H). LCMS Rt=1.020 min in 2 min
chromatography, MS ESI calcd. for C.sub.24H.sub.37N.sub.3O.sub.2
[M+H].sup.+ 400, found 422 [M+23].sup.+.
Example 10. Synthesis of 18 and 19
##STR00052##
[0350] Step 1. Synthesis of A26 and A27.
[0351] To a solution of A23 (600 mg, 1.5 mmol, 1.00 eq) in acetone
(10 mL) was added K.sub.2CO.sub.3 (414 mg, 3 mmol, 2 eq) and
2H-benzo[d][1,2,3] triazole (268 mg, 2.25 mmol, 1.5 eq). The
mixture was stirred at 25.degree. C. for 12 hours. The reaction was
quenched by water (50 mL) and then extracted with EA (50 mL*2). The
combined organic phase was washed with saturated brine, dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated in vacuum.
The residue was purified by silica gel chromatography (100-200 mesh
silica gel, Petroleum ether/Ethyl acetate=5/1) to afford A26 (170
mg, 292 umol, 19.4% yield, 75% purity) and A27 (405 mg, 883 umol,
58.8% yield, 95% purity) as off-white solids.
[0352] .sup.1H NMR (A26): (CDCl.sub.3, 400 MHz) .delta. 7.89-7.88
(m, 2H), 7.42-7.40 (m, 2H), 5.60-5.50 (m, 2H), 2.71-2.67 (m, 1H),
2.23-2.15 (m, 2H), 0.77 (s, 3H).
[0353] .sup.1H NMR (A27): (CDCl.sub.3, 400 MHz) .delta. 8.10 (d,
J=8.4 Hz, 1H), 7.51-7.50 (m, 1H), 7.42-7.35 (m, 2H), 5.49-5.39 (m,
2H), 2.76-2.74 (m, 1H), 2.23-2.16 (m, 2H), 0.76 (s, 3H).
[0354] Step 2. Synthesis of 18 and 19.
[0355] To a solution A26 (170 mg, 390 umol, 1.00 eq) and KOH (43.7
mg, 780 umol, 2 eq) in THF (3.00 mL) was added CH.sub.3I (66.4 mg,
468 umol, 1.2 eq). The mixture was stirred at 25.degree. C. for 16
hrs. Then, the reaction was quenched with water and extracted with
EA (2*30 mL), the combined organic phase was washed with brine and
dried over Na.sub.2SO.sub.4, filtered and concentrated. The residue
was purified by Prep-HPLC (0.5% HCl) to afford compound 18 (28 mg,
16% yield) and compound 19 (18.5 mg, 10.5% yield) as off white
solids.
[0356] .sup.1H NMR (18) (CDCl.sub.3, 400 MHz) .delta. 7.96-7.87 (m,
2H), 7.48-7.39 (m, 2H), 5.57-5.52 (m, 1H), 2.33-2.29 (m, 1H),
2.23-2.11 (m, 1H), 1.99-1.91 (m, 1H), 1.86-1.74 (m, 5H), 1.71-1.60
(m, 2H), 1.53-1.52 (m, 3H), 1.39-0.87 (m, 16H), 0.71 (s, 3H),
0.61-0.69 (m, 2H). LCMS Rt=1.285 min in 2 min chromatography, MS
ESI calcd. for C.sub.28H.sub.39N.sub.3O.sub.2 [M+H].sup.+ 450,
found 432 [M+H-18].
[0357] .sup.1H NMR (19) (CDCl.sub.3, 400 MHz) .delta. 7.95-7.86 (m,
2H), 7.45-7.37 (m, 2H), 5.76-5.67 (m, 1H), 2.80-2.70 (m, 1H),
2.28-2.09 (m, 2H), 2.00 (d, J=7.28 Hz, 3H), 1.91-1.53 (m, 9H),
1.46-1.30 (m, 4H), 1.27-0.96 (m, 10H), 0.75 (s, 3H), 0.71-0.68 (m,
2H). LCMS Rt=1.248 min in 2 min chromatography, MS ESI calcd. for
C.sub.28H.sub.39N.sub.3O.sub.2 [M+H].sup.+ 450, found 432
[M+H-18].sup.+
Example 11. Synthesis of 20 and 21
##STR00053##
[0359] To a solution of A27 (405 mg, 929 umol, 1.00 eq) and KOH
(103 mg, 1.85 mmol, 2 eq) in THF (6.00 mL) was added CH.sub.3I (157
mg, 1.11 mmol, 1.2 eq). The mixture was stirred at 25.degree. C.
for 5 hrs. Then, the reaction was quenched with water and extracted
with EA (2*50 mL), the combined organic phase was washed with brine
and dried over Na2SO4, filtered and concentrated. The residue was
purified by Prep-HPLC (0.5% HCl) to afford compound 20 (107 mg, 26%
yield) and compound 21 (64 mg, 15% yield) as off white solids.
[0360] .sup.1H NMR (20): (CDCl.sub.3, 400 MHz) .delta. 8.12 (d, J=8
Hz, 1H), 7.53-7.47 (m, 1H), 7.45-7.38 (m, 2H), 5.70-5.61 (m, 1H),
2.42-2.34 (m, 1H), 2.17-2.06 (m, 1H), 1.94-1.87 (m, 1H), 1.86-1.79
(m, 1H), 1.79-1.75 (m, 3H), 1.74-1.63 (m, 2H), 1.63-1.49 (m, 6H),
1.44-1.23 (m, 5H), 1.21 (s, 3H), 1.16-0.85 (m, 6H), 0.71 (s, 3H),
0.68-0.60 (m, 2H). LCMS SAGE-WZF-010-P2B Rt=1.195 min in 2 min
chromatography, MS ESI calcd. for C.sub.28H.sub.39N.sub.3O.sub.2
[M+H].sup.+ 450, found 450.
[0361] .sup.1H NMR (21): (CDCl.sub.3, 400 MHz) .delta. 8.09 (d,
J=12 Hz, 1H), 7.58 (d, J=8 Hz, 1H), 7.49 (m, t, J=8 Hz, 1H), 7.39
(t, J=8 Hz, 1H), 5.85-5.76 (m, 1H), 2.78-2.70 (m, 1H), 2.15-2.00
(m, 2H), 1.93 (d, J=7.28 Hz, 3H), 1.88-1.52 (m, 9H), 1.41-1.29 (m,
4H), 1.26-0.49 (m, 10H), 0.73-0.68 (m, 2H), 0.65 (s, 3H). LCMS
Rt=1.178 min in 2 min chromatography, MS ESI calcd. for
C.sub.28H.sub.39N.sub.3O.sub.2 [M+H].sup.+ 450, found 450
Assay Methods
[0362] Compounds provided herein can be evaluated using various
assays; examples of which are described below.
Steroid Inhibition of TBPS Binding
[0363] TBPS binding assays using rat brain cortical membranes in
the presence of 5 .mu.M GABA has been described (Gee et al, J.
Pharmacol. Exp. Ther. 1987, 241, 346-353; Hawkinson et al, Mol.
Pharmacol. 1994, 46, 977-985; Lewin, A. H et al., Mol. Pharmacol.
1989, 35, 189-194).
[0364] Briefly, cortices are rapidly removed following decapitation
of carbon dioxide-anesthetized Sprague-Dawley rats (200-250 g). The
cortices are homogenized in 10 volumes of ice-cold 0.32 M sucrose
using a glass/teflon homogenizer and centrifuged at 1500.times.g
for 10 min at 4.degree. C. The resultant supernatants are
centrifuged at 10,000.times.g for 20 min at 4.degree. C. to obtain
the P2 pellets. The P2 pellets are resuspended in 200 mM NaCl/50 mM
Na--K phosphate pH 7.4 buffer and centrifuged at 10,000.times.g for
10 min at 4.degree. C. This washing procedure is repeated twice and
the pellets are resuspended in 10 volumes of buffer. Aliquots (100
.mu.L) of the membrane suspensions are incubated with 3 nM
[.sup.35S]-TBPS and 5 .mu.L aliquots of test drug dissolved in
dimethyl sulfoxide (DMSO) (final 0.5%) in the presence of 5 .mu.M
GABA. The incubation is brought to a final volume of 1.0 mL with
buffer. Nonspecific binding is determined in the presence of 2
.mu.M unlabeled TBPS and ranged from 15 to 25%. Following a 90 min
incubation at room temp, the assays are terminated by filtration
through glass fiber filters (Schleicher and Schuell No. 32) using a
cell harvester (Brandel) and rinsed three times with ice-cold
buffer. Filter bound radioactivity is measured by liquid
scintillation spectrometry. Non-linear curve fitting of the overall
data for each drug averaged for each concentration is done using
Prism (GraphPad). The data are fit to a partial instead of a full
inhibition model if the sum of squares is significantly lower by
F-test. Similarly, the data are fit to a two component instead of a
one component inhibition model if the sum of squares is
significantly lower by F-test. The concentration of test compound
producing 50% inhibition (IC.sub.50) of specific binding and the
maximal extent of inhibition (I.sub.max) are determined for the
individual experiments with the same model used for the overall
data and then the means.+-.SEM.s of the individual experiments are
calculated. Picrotoxin serves as the positive control for these
studies as it has been demonstrated to robustly inhibit TBPS
binding.
[0365] Various compounds are or can be screened to determine their
potential as modulators of [.sup.35S]-TBPS binding in vitro. These
assays are or can be performed in accordance with the above
discussed procedures.
[0366] For Table 1, "A" indicates an IC.sub.50<50 nM, "B"
indicates an IC.sub.50 of 50 nM to 100 nM, "C" indicates an
IC.sub.50 100 nM to 250 nM, "D" indicates an IC.sub.50 of 250 nM to
500 nM, and "E" indicates IC.sub.50>500 nM.
TABLE-US-00001 TABLE 1 35S-TBPS Radioligand Displacement Compound
(IC.sub.50) 1 D 2 B 3 A 4 B 5 D 6 A 7 D 8 D 9 D 10 A 11 D 12 C 13 C
14 E 15 E 16 E 17 E 18 B 19 E 20 E 21 C
* * * * *